[
{"heading": [[]], "sub_heading": [[]], "time": [[]], "publisher": [["PTI"]], "article": [[]], "tags": []},
{"heading": [["Government has decided to disinvest in certain pharma PSUs: Piyush Goyal"]], "sub_heading": [["During his interaction with the captains of the pharmaceutical industry, and office-bearers of the pharma associations through the video conference, he also said that the country should become Aatmanirbhar in Active Pharmaceutical Ingredients (API)."]], "time": [["Last Updated: May 31, 2020, 07.28 PM IST"]], "publisher": [[", ET Bureau"]], "article": [["NEW DELHI: Commerce and industry minister ", "Piyush Goyal", " on Sunday said the government has decided to disinvest in certain pharmaceutical public sector undertakings (PSU) and invited the Indian companies to use PSUs for plug and play model of manufacturing.\n", "\n", "During his interaction with the captains of the pharmaceutical industry, and office-bearers of the pharma associations through the video conference, he also said that the country should become Aatmanirbhar in Active Pharmaceutical Ingredients (API).\n", "\n", "\u201cThe government has decided to disinvest in certain pharma PSUs, the minister invited the Indian companies to use PSUs for plug and play model of manufacturing,\u201d Goyal was quoted saying in an official release.\n", "\n", "The government had in 2016 decided to close Indian Drugs and Pharmaceutical Limited and ", "Rajasthan Drugs and Pharmaceuticals Limited", ". It had also announced strategic sale of ", "Hindustan Antibiotics Limited", " and Bengal Chemicals and Pharmaceutical Limited.\n", "\n", "India's Pharma exports rose 8.2% on year to $20.7 billion in 2019-20 from $19.14 billion in 2018-19. \n", "\n", "On the API front, Goyal said the government has already approved the scheme on ", "Promotion of Bulk Drug Parks", " for financing Common Infrastructure Facilities in three Bulk Drug Parks. Production Linked Incentive Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country has been given a go ahead.\n", "\n", "Goyal asked industry to look at the large untapped market in Eastern Europe and Russia, and said that anti-dumping investigation process has been expedited. He also asked industry to bring to his notice if it faces any roadblock or unfair competition in a country, with which India has a ", "free trade agreement", " (FTA).\n", "\n", "During the ongoing Covid-19 pandemic, India, he said, has been recognized as the \u2018Pharmacy of the World\u2019, as over 120 countries got some essential medicines in the last two months, including 40 of them getting them in the form of grant, free of cost.\n", "\n"]], "tags": ["Hindustan Antibiotics Limited", "promotion of bulk drug parks", "active pharmaceutical ingredients (api", "Rajasthan Drugs and Pharmaceuticals Limited", "piyush goyal", "Free Trade Agreement"]},
{"heading": [["Remdesivir use may be managed by government"]], "sub_heading": [["The recommendations come as four Indian drug companies, Cipla, Hetero, Mylan and Jubilant, gear up to get an approval for the drug in the treatment of Covid-19."]], "time": [["Last Updated: Jun 01, 2020, 07.06 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["MUMBAI: The subject expert committee of the Drug Controller of India has suggested that drugmaker Gilead\u2019s experimental drug remdesivir should be administered under a \u2018compassionate use\u2019 programme and not sold directly to private hospitals, considering that the drug is still under trial. \n", "\n", "This essentially means that the companies which have got the licence to manufacture the drug will have to sell it to government institutions, ET has learnt from officials aware of the development. \n", "\n", "The recommendations come as four Indian drug companies, Cipla, Hetero, ", "Mylan", " and Jubilant, gear up to get an approval for the drug in the treatment of Covid-19.\n", "\n", "Remdesivir received an emergency authorisation approval in countries like US and Japan, and in US its distribution is controlled. \n", "\n", "The US Food and Drug Administration", " (FDA), while giving its emergency approval, has restricted supply where it said that distribution of the drug will be controlled by the US government. \n", "\n", "The US FDA", " directed that Gilead will supply the drug to authorised distributors, or directly to a US government agency, who will then distribute to hospitals and other healthcare facilities as directed by the government, in collaboration with the state as well as local government authorities. \n", "\n", "\u201cSince most patients who are currently being treated for Covid-19 are in public hospitals and since the efficacy is still not known, this seems to be the thinking,\u201d said an official who was aware of the development and did not wish to be quoted due to the sensitivity of the issue. \n", "\n", "In case of remdesivir, Indian companies have asked for a trial waiver. \n", "\n", "\"In India, if the Indian health ministry introduced the drug out of clinical trials, it should ensure that the guidelines are in place for informed consent and monitored emergency use of remdesvir, the results of which are documented and shared in a timely manner with the wider medical and scientific community,\" said Leena Menghaney, who is a lawyer with Doctors Without Borders.\n", "\n"]], "tags": ["Gilead Sciences", "M\u00c3\u00a9decins Sans Fronti\u00c3\u00a8res", "Mylan", "The US Food and Drug Administration", "the us fda"]},
{"heading": [["Scientists question validity of major hydroxychloroquine study"]], "sub_heading": [["In an open letter to The Lancet\u2019s editor, Richard Horton, and the paper\u2019s authors, the scientists asked the journal to provide details about the provenance of the data and called for the study to be independently validated by the World Health Organization or another institution."]], "time": [["Last Updated: May 30, 2020, 10.37 AM IST"]], "publisher": [["New York Times"]], "article": [["\n", "\n", "More than 100 scientists and clinicians have questioned the authenticity of a massive hospital database that was the basis for an influential study published last week that concluded that treating people who have COVID-19 with ", "chloroquine", " and hydroxychloroquine did not help and might have increased the risk of abnormal heart rhythms and death.\n", "\n", "In an open letter to The Lancet\u2019s editor, Richard Horton, and the paper\u2019s authors, the scientists asked the journal to provide details about the provenance of the data and called for the study to be independently validated by ", "the World Health Organization", " or another institution.\n", "\n", "A spokeswoman for Dr. Mandeep Mehra, the Harvard professor who was the paper\u2019s lead author, said Friday that the study\u2019s authors had asked for an independent academic review and audit of their work.\n", "\n", "Use of the malaria drugs chloroquine and hydroxychloroquine to prevent and treat COVID-19 has been a focus of intense public attention. President Donald Trump has promoted the promise of hydroxychloroquine, despite the absence of gold-standard evidence from randomized clinical trials to prove its effectiveness, and recently said he was taking it himself in hopes of preventing ", "coronavirus", " infection.\n", "\n", "The scientists\u2019 challenges to the Lancet paper come at a time of increasing debate about the risks of the rush to publish new medical findings about COVID-19. The paper, published May 22, included data on tens of thousands of patients hospitalized through April 14, meaning that the authors analyzed the trove of data, wrote the paper and went through the journal\u2019s peer review of its findings in just over five weeks, much faster than usual.\n", "\n", "The experts who wrote The Lancet also criticized the study\u2019s methodology and the authors\u2019 refusal to identify any of the hospitals that contributed patient data or to name the countries where they were located. The company that owns the database is Surgisphere, based in Chicago.\n", "\n", "\u201cData from Africa indicate that nearly 25% of all COVID-19 cases and 40% of all deaths in the continent occurred in Surgisphere-associated hospitals, which had sophisticated electronic patient data recording,\u201d the scientists wrote. \u201cBoth the numbers of cases and deaths, and the detailed data collection, seem unlikely.\u201d\n", "\n", "Another of the critics\u2019 concerns was that the data about COVID-19 cases in Australia was incompatible with government reports and included \u201cmore in-hospital deaths than had occurred in the entire country during the study period.\u201d\n", "\n", "A spokeswoman for The Lancet, Emily Head, said in an email that the journal had received numerous inquiries about the paper and had referred the questions to the authors.\n", "\n", "\u201cWe will provide further updates as necessary,\u201d she said. \u201cThe Lancet encourages scientific debate and will publish responses to the study, along with a response from the authors, in the journal in due course.\u201d\n", "\n", "Dr. Sapan Desai, owner and founder of Surgisphere and one of the paper\u2019s authors, vigorously defended the findings and the authenticity and validity of the company\u2019s database. He said official counts of coronavirus cases and deaths often lagged behind actual cases, which might explain some discrepancies.\n", "\n", "The paper\u2019s authors said they had analyzed data gathered from 671 hospitals on six continents that shared granular medical information about nearly 15,000 patients who had received the drugs and 81,000 who had not, while shielding their identities.\n", "\n", "\u201cWhat the world has to understand is that this is registry-based data,\u201d Desai said. \u201cWe have no control over the source of the information. All we can do is report the data that is given to us.\u201d\n", "\n", "Another group of researchers from the Barcelona Institute for Global Health also raised questions about the Surgisphere database, both with the authors and editors of The Lancet.\n", "\n", "Scientists who wrote and signed the letter criticizing the study included clinicians, researchers, statisticians and ethicists from academic medical centers, including Harvard\u2019s T.H. Chan School of Public Health, the University of Pennsylvania, Vanderbilt University and ", "Duke University", ".\n", "\n", "One of the signatories, Dr. Adrian Hernandez, who heads the Duke Clinical Research Institute, said the paper contained many troubling anomalies, \u201cbut the biggest thing that raised a red flag was that here was such a large database across more than 600 hospitals, and no one had really known about its existence. That was quite remarkable.\u201d\n", "\n", "Like several other signatories of the letter, Hernandez is involved in a clinical trial of hydroxychloroquine to see if it can protect health care workers from infection.\n", "\n", "Allen Cheng, a professor of infectious diseases at Monash University in Melbourne, Australia, who also signed the letter, said in an email that the individual hospitals included in the database should be identified.\n", "\n", "\u201cIdeally, the database should be made public, but if that isn\u2019t possible, it should at least be independently reviewed and an audit performed,\u201d he said.\n", "\n", "Surgisphere\u2019s data was also the basis of a study of coronavirus patients published in The New England Journal of Medicine this month by some of the same authors, including Desai and Harvard\u2019s Mehra, as well as for two versions of an article on the use of an antimicrobial drug to treat COVID-19 that were not published in an established medical journal.\n", "\n", "Jennifer Zeis, a spokeswoman for The New England Journal of Medicine, said by email that the journal was aware of the questions that had been raised and was looking into them.\n", "\n", "Mehra issued a statement Friday, saying that the paper\u2019s authors \u201cleveraged the data available through Surgisphere to provide observational guidance to inform the care of hospitalized COVID-19 patients\u201d because the results of randomized clinical trials would not be available for some time.\n", "\n", "Other observational studies had previously reported possible harms associated with the malaria drugs, and the Food and Drug Administration had issued a safety warning about their use. After the Lancet paper was published, the World Health Organization and other organizations suspended clinical trials of the drugs.\n", "\n"]], "tags": ["Chloroquine", "the World Health Organization", "Harvard University", "hydrochloroquine", "Duke University", "coronavirus"]},
{"heading": [["US pharma giant seeks marketing authorisation from India for remdesivir"]], "sub_heading": [["\"Gilead Sciences has applied seeking marketing authorisation for its anti-viral drug remdesivir to India's Central Drugs Standard Control Organisation (CDSCO). The CDSCO will examine the application with the help of the expert committee. It will take a final decision based on the recommendations of the expert committee,\" a source said."]], "time": [["Last Updated: May 30, 2020, 10.28 AM IST"]], "publisher": [["PTI"]], "article": [["NEW DELHI: A US pharmaceutical giant has applied to India's drug regulator seeking marketing authorisation for its anti-viral drug ", "remdesivir", ", which is being touted as a potential treatment for COVID-19.\n", "\n", "Gilead Sciences, who is the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir, sources said.\n", "\n", "\"The company has applied seeking marketing authorisation for its anti-viral drug remdesivir to India's Central Drugs Standard Control Organisation (CDSCO). The CDSCO will examine the application with the help of the expert committee. It will take a final decision based on the recommendations of the expert committee,\" a source said.\n", "\n", "The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (FDA) to treat hospitalised ", "coronavirus", " patients.\n", "\n", "Regulatory approval", " under exceptional pathway was granted by the Japanese Ministry of Health, Labour and Welfare on May 7, on the basis of clinical data from the US, sources said.\n", "\n", "On the basis of approvals granted by USFDA or any other reputed regulator, the Indian regulator can approve the drug by waiving off clinical trials in special circumstances in accordance with the provisions of the New Drug and Clinical Trial Rules 2019, a source in the know of the developments said.\n", "\n", "This comes in the backdrop of two Indian pharmaceutical companies -- Cipla and Hetero Labs -- applying to the drug regulator seeking permission to manufacture and sell remdesivir in India.\n", "\n", "They have also sought a clinical trial waiver for remdesivir so that the medicine can be made available for the patients faster, an official said.\n", "\n", "Their applications are still under consideration, the official said.\n", "\n", "Gilead Sciences Inc", " have entered into non-exclusive licensing agreements with pharma firms, including three domestic majors Cipla, Jubilant Life Sciences and Hetero, for manufacture and distribution of remdesivir.\n", "\n", "The Indian Council of Medical Research had earlier said anti-viral medication remdesivir, which was used during Ebola outbreak, might inhibit the SARS-CoV-2 replication and research on its efficacy in the treatment of COVID-19 is a part of the WHO's 'solidarity trial'.\n", "\n", "According to a recently-published study in the New England Journal of Medicine, two out of three critically-ill coronavirus patients, who were on oxygen support, showed signs of improvement when they were administered remdesivir.\n", "\n", "All new drugs have to undergo trials before getting approval for marketing them in India.\n", "\n", "But the New Drug and Clinical Trial Rules, 2019, provide for certain clauses, according to which the provision of waiver of local phase-III clinical trials of the drug is approved and marketed in certain countries (as notified from time to time) subject to certain conditions, like national emergency or epidemics, in public interest.\n", "\n"]], "tags": ["pharmaceutical industry", "Gilead Sciences Inc", "coronavirus", "regulatory approval", "remdesivir"]},
{"heading": [["Government to divest stake in some pharma PSUs: Goyal"]], "sub_heading": [["The government had in 2016 decided to close Indian Drugs and Pharmaceutical Ltd and Rajasthan Drugs and Pharmaceuticals Ltd. It had also announced strategic sale of Hindustan Antibiotics Ltd and Bengal Chemicals and Pharmaceutical Ltd."]], "time": [["Last Updated: Jun 01, 2020, 07.13 AM IST"]], "publisher": [["ET Bureau"]], "article": [["NEW DELHI: The government has decided to disinvest in certain public sector undertakings (", "PSU", ") in the pharmaceutical sector, commerce and industry minister Piyush Goyal said on Sunday, and invited Indian companies to use PSUs for a plug and play manufacturing model.\n", "\n", "Goyal, during an video interaction with captains of the pharmaceutical industry and office-bearers of pharma associations, also said that the country should become Aatmanirbhar (self-reliant) in Active Pharmaceutical Ingredients (API), the basic ingredients for drugs.\n", "\n", "\u201cThe government has decided to disinvest in certain pharma PSUs, the minister invited the Indian companies to use PSUs for plug and play model of manufacturing,\u201d Goyal was quoted saying in an official press release.\n", "\n", "The government had in 2016 decided to close Indian Drugs and Pharmaceutical Ltd and ", "Rajasthan Drugs and", " Pharmaceuticals Ltd. It had also announced strategic sale of ", "Hindustan Antibiotics", " Ltd and ", "Bengal Chemicals and Pharmaceutical Ltd.", "\n", "\n", "On the API front, Goyal said the government has already approved a scheme for promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks. Production Linked Incentive Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country has been given approval.\n", "\n", "Goyal asked industry to look at the large untapped market in Eastern Europe and Russia and said that the anti-dumping investigation process has been expedited.\n", "\n"]], "tags": ["PSU", "bengal chemicals and pharmaceutical ltd.", "rajasthan drugs and", "active pharmaceutical ingredients (api", "Hindustan Antibiotics"]},
{"heading": [["Nicotex joins hands with Karnataka, Goa governments to encourage smoking cessation with NRT"]], "sub_heading": [["To promote safe behaviour, Nicotex has collaborated with the efforts of Karnataka to protect the frontline workers, who are presently engaged in field work under high vulnerability amidst the COVID-19 outbreak."]], "time": [["Last Updated: May 30, 2020, 03.49 PM IST"]], "publisher": [["PTI"]], "article": [["MUMBAI: Nicotex, ", "Cipla Health", "'s ", "smoking cessation", " brand, on Saturday said it has collaborated with Karnataka and Goa governments to provide ", "Nicotine Replacement Therapy", " (", "NRT", ") to frontline workers.\n", "\n", "\"Especially during the COVID-19 pandemic, smokers are at a greater risk. Our collaborations with the Health Ministry of various states are helping us to execute these operations at a much larger scale and to reach out to the masses to help them quit smoking.\n", "\n", "\"We are striving to further enhance the scale of our initiatives and are working towards partnering with other states in the days to come,\" Cipla Health CEO Shivam Puri said in a statement. \n", "\n", "To promote safe behaviour, Nicotex has collaborated with the efforts of Karnataka to protect the frontline workers, who are presently engaged in field work under high vulnerability amidst the COVID-19 outbreak.\n", "\n", "With distribution of over 40,000 Nicotex packs to over 10,000 ", "healthcare", " workers, the therapy (NRT), as per WHO, would benefit smokers, gutka and other smokeless tobacco users by reducing cravings, anxiety, irritability and other withdrawal symptoms associated with smoking cessation.\n", "\n", "In Goa, the collaborative efforts of the state and Cipla Health have enabled various grassroot-levels health seeking measures dissuading the consumption of tobacco among its citizens.\n", "\n", "With the launch of ''Mission Tobacco Free Goa'', the state has been working towards making two talukas tobacco-free zones while simultaneously working on having the same effect across the state.\n", "\n"]], "tags": ["NRT", "Cipla Health", "nicotine", "nicotine replacement therapy", "Smoking cessation", "healthcare"]},
{"heading": [["BDR in pact to make Gilead drug for Cipla"]], "sub_heading": [["In late May, BDR had sought the approval of India\u2019s drug regulator to make and sell remdesivir in India without entering into an arrangement with Gilead. The Mumbai-based company has now signed a contract to make the drug for Cipla, which is one of the licensed companies."]], "time": [["Last Updated: Jun 01, 2020, 07.08 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["NEW DELHI: ", "BDR Pharmaceuticals", " has signed a contract-manufacturing deal with ", "Cipla", " for remdesivir, a patented product of US company ", "Gilead Sciences", " and the only drug approved to treat Covid-19 patients.\n", "\n", "In late May, BDR had sought the approval of India\u2019s drug regulator to make and sell remdesivir in India without entering into an arrangement with Gilead. The Mumbai-based company has now signed a contract to make the drug for Cipla, which is one of the licensed companies, people aware of the matter told ET.\n", "\n", "Following BDR\u2019s request for approval to sell the drug, Gilead, which has signed voluntary licensing agreements with Cipla, ", "Hetero Labs", " and Jubilant Life Sciences for the manufacture and sale of remdesivir in 127 poor and middle-income nations including India, had flagged concerns over the Mumbai company\u2019s entry into the fray. The US company had written to the Indian government seeking its intervention and support for applications of the \u201cpatent holder\u201d and not for \u201cnon-licensees.\u201d\n", "\n", "It is not known if Gilead has permitted its licensees to enter into sub-licensing manufacturing contracts.\n", "\n", "\u201cIn this case, BDR gets covered by the licensee holder Cipla to manufacture and hence none of the companies should have an objection. However, since the terms and conditions of Gilead\u2019s voluntary licence are not in the public domain, nobody can comment on how this will pan out,\u201d a pharma analyst said on condition of anonymity. Cipla declined to comment on the development.\n", "\n", "\u201cThere is too much ambiguity. We don\u2019t know if BDR can benefit from Gilead\u2019s data on the drug and can manufacture it. We don\u2019t know if Gilead\u2019s contract allows sub-licensing,\u201d another pharma analyst said. ", "Dharmesh Shah", ", MD of BDR, said \u201cnothing is more important than accessibility and affordability for Covid-19 patients and if remdesivir is working, it should be available soon.\u201d Shah said his company has the active pharmaceutical ingredients needed to make remdesivir, without divulging details about the BDR-Cipla tie-up.\n", "\n", "Gilead did not respond to e-mailed queries on this issue.\n", "\n"]], "tags": ["cipla", "Gilead Sciences", "BDR Pharmaceuticals", "Dharmesh Shah", "Hetero Labs"]},
{"heading": [["Local Pharma API companies to gain from Rs 10,000 crore scheme"]], "sub_heading": [["The incentive \u2014 part of a .`10,000-crore production-linked incentive scheme to boost domestic manufacturing of critical bulk drugs and APIs approved by the Cabinet in March \u2014 will be given to companies investing on greenfield plants to manufacture 53 crucial APIs."]], "time": [["Last Updated: Jun 02, 2020, 07.01 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["New Delhi: The government will provide an incentive of Rs 10 crore each to domestic companies setting up plants to produce 53 crucial active pharmaceutical ingredients (APIs) for which the ", "domestic drug industry", " is vulnerably dependent on imports from China. \n", "\n", "The incentive \u2014 part of a Rs 10,000-crore production-linked ", "incentive scheme", " to boost ", "domestic manufacturing", " of critical bulk drugs and APIs approved by the Cabinet in March \u2014 will be given to companies investing on greenfield plants to manufacture 53 crucial APIs of anti-TB drugs, steroids, vitamins, etc, with the rider that they must supply to domestic drug makers. \n", "\n", "\u201cThe scheme is applicable for domestic consumption only,\u201d a government official told ET on condition of anonymity. \n", "\n", "The scheme also proposes annual incentive of Rs 720 crore for crucial fermentation products including ", "penicillin G", " (used to manufacture antibiotics), amino cephalosporanic acid 7-ACA (used in manufacturing antimicrobial drugs), clavulanic acid (to treat bacterial infections), and erythromycin thiocynate (antiinfectives), said the official .\n", "\n", "Indian pharmaceuticals industry is the third largest in the world, but it is dependent on China for crucial raw material. The new scheme seeks to reduce this dependency and ensure adequate domestic supply of bulk drugs and APIs. \n", "\n", "Contours of the scheme were discussed with the stakeholders by a technical committee formed by the pharmaceuticals department (DoP) last month. For speedy introduction of the scheme, the government proposes to disburse funds within 60 days of receipt of claim, according to the technical panel\u2019s proposal. Firms whose cost of production is comparable or less than import price of APIs and bulk drugs will get priority, it said. ET has seen a copy of the proposal.\n", "\n", "\u201cIf no investment has been made by the manufacturer within six months from date of approval, the bank guarantee shall be forfeited and the manufacturer shall no longer remain a beneficiary under the scheme,\u201d said the official cited earlier. The government has also proposed creation of two bulk drug parks and one intermediate park with investment incentive of up to Rs 1,000 crore each.\n", "\n"]], "tags": ["Penicillin", "domestic manufacturing", "penicillin G", "Incentive Scheme", "domestic drug industry"]},
{"heading": [["Biocon's partner Mylan gets favourable ruling from US patent authority for 4 devices"]], "sub_heading": [["\"We are extremely pleased with the US PTAB's ruling in favour of our partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. This strengthens our resolve to provide a high quality affordable Insulin Glargine to diabetic patients in the US and generate savings for their healthcare system,\" Biocon Biologics CEO and MD Christiane Hamacher said."]], "time": [["Last Updated: Jun 01, 2020, 03.41 PM IST"]], "publisher": [["PTI"]], "article": [["New Delhi: Biotechnology major Biocon on Monday said the US patent authority has ruled in favour of its partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. The favourable ruling in inter-parts review proceedings by ", "the Patent and Trademark Appeal Board", " (PTAB) would pave the way for launch of insulin product Glargine in the US, Biocon said in a filing to BSE. \n", "\n", " \"We are extremely pleased with the US PTAB's ruling in favour of our partner Mylan for four device patents of Sanofi's Lantus SoloSTAR. This strengthens our resolve to provide a high quality affordable Insulin Glargine to diabetic patients in the US and generate savings for their healthcare system,\" ", "Biocon Biologics", " CEO and MD Christiane Hamacher said. \n", "\n", " A new drug application (", "NDA", ") of Biocon's partner for Semglee is under active review by the ", "USFDA", " and this favourable ruling further clears the path for the anticipated launch of our Glargine in the US in mid-CY2020, she added. \n", "\n", " The Patent and Trademark Appeal Board found all challenged claims of Sanofi's Lantus SoloSTAR device patents -- US Patent Nos. 8,603,044, 8,992,486, and 9,526,844 unpatentable in inter-partes review (", "IPR", ") proceedings, Biocon said. \n", "\n", " \"The PTAB found three claims of the 9,604,008 patent unpatentable, and two claims to be patentable. However, Mylan and Biocon have previously obtained a covenant not to sue from Sanofi on the '008 patent and therefore this ruling does not impact Biocon and Mylan's ability to commercialize Semglee (insulin glargine) upon final approval from the US Food and Drug Administration,\" it added. \n", "\n", " \"Once approved and commercialized our co-developed Semglee will expand access to insulin therapy,\" it added. \n", "\n", "Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and pediatric patients with type 1 diabetes for the control of high blood sugar, the filing said. \n", "\n", "Sanofi sells the product in vials (Lantus) and as a disposable injection pen (Lantus SoloSTAR), it added. \n", "\n", " \"Sanofi's total IQVIA sales for the 12 months ending March 31, 2020, were approximately USD 1.71 billion for Lantus 100 Units/mL and about USD 4.32 billion for Lantus SoloSTAR,\" the filing said. \n", "\n", " Shares of Biocon Ltd were trading at Rs 370.35 per scrip on BSE, up 4.41 per cent from the previous close.\n"]], "tags": ["USFDA", "the patent and trademark appeal board", "Biocon Biologics", "NDA", "IPR"]},
{"heading": [["Russian drug to treat Covid to be delivered to hospitals in June"]], "sub_heading": [["Avifavir is Russia\u2019s first COVID-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials. Avifavir has received a registration certificate from the Ministry of Health of the Russian Federation. Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19."]], "time": [["Last Updated: Jun 01, 2020, 12.28 PM IST"]], "publisher": [[", ET Bureau"]], "article": [["NEW DELHI: The drug to treat Covid patients created by Russia will be supplied to country\u2019s hospitals this June in what can mark a significant achievement in the fight against the pandemic.\n", "\n", "Russian Direct Investment Fund (RDIF), Russia\u2019s sovereign wealth fund, and the ChemRar Group will deliver 60,000 courses of ", "Avifavir", " to Russian hospitals this month.\n", "\n", "Avifavir is Russia\u2019s first COVID-19 drug and has shown high efficacy in treating patients with ", "coronavirus", " during clinical trials. Avifavir has received a registration certificate from the Ministry of Health of the Russian Federation. Thus, Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19.\n", "\n", "In early June, the first batches of Avifavir will be sent to Russia\u2019s Federal Service for Surveillance in Healthcare (Roszdravnadzor) for approval for use. Deliveries of the first batches of the drug to Russian hospitals are expected on June 11, according to a statement by RDIF and ChemRar. The high quality of Avifavir is due to more stringent requirements for its active pharmaceutical ingredient, compared with the requirements for active pharmaceutical ingredients in international markets, RDIF and ChemRar claimed.\n", "\n", "Avifavir, which disrupts the reproduction mechanisms of coronavirus, is the first Russian direct-acting antiviral drug that has proven effective in clinical trials. The drug has been well studied, since it has been used in Japan since 2014 against severe forms of influenza.\n", "\n", "The intermediate data from the Avifavir clinical trials confirm its high efficacy against COVID-19. The final stage of Avifavir clinical trials involving 330 patients, approved by the Russian Ministry of Health on May 21 is ongoing. The number of medical centers approved for the participation in Avifavir clinical trials has increased from 30 to 35 across Russia\u2019s regions, according to RDIF and ChemRar.\n", "\n", "The drug proved to be highly effective during the clinical trials involving I.M. Sechenov First Moscow State Medical University, Lomonosov Moscow State University and other medical and academic institutions.\n", "\n", "Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said, \u201cRDIF and ChemRar, in close collaboration with the Ministry of Health, have swiftly produced and registered a drug that surpasses its global peers not only in terms of effectiveness, but also of safety. Avifavir more than halves the duration of the disease, ensuring most patients are free of infection after the fifth day of treatment, which helps to more successfully fight the virus and protects Russian hospitals from being overwhelmed. Afivavir is not only the first antiviral drug registered against coronavirus in Russia, but it is also perhaps the most promising anti-COVID-19 drug in the world. It was developed and tested in clinical trials in Russia in an unprecedented short period of time, enabling Afivavir to become the world\u2019s first registered drug based on Favipiravir.\u201d\n", "\n", " \n", "\u2014 According to the results of the 10 days of the clinical trials, Avifavir demonstrated safety with no new or previously unreported side effects detected;\n", "\n", "\u2014 Median elimination of the virus took four days compared to nine days with standard therapy, according to the study;\n", "\n", "\u2014 Efficacy of the drug is above 80%, a criterion for a drug with high antiviral activity;\n", "\n", "\u2014 Following the first four days of treatment, 65% of the 40 patients who took Avifavir tested negative for coronavirus, which is twice as many as in the standard therapy group. By day 10, the number of patients whose tests returned negative results reached 90%;\n", "\n", "\u2014 The body temperature of 68% of patients taking Avifavir returned to normal earlier (on the third day) than in the control group (on the sixth day);\n", "\n", "\u2014 The drug is undergoing trials in Moscow, Saint-Petersburg, Tver, Nizhny Novgorod, Smolensk, Ryazan, Kazan, Ufa and in the Republic of Dagestan.\n", "\n"]], "tags": ["russian drug", "coronavirus medicine", "covid medicine", "coronavirus", "covid drug", "avifavir"]},
{"heading": [["Tata Group ties up with SCTIMST for commercial production of COVID-19 testing kits"]], "sub_heading": [["The tie with city-based SCTIMST follows Tata Sons partnership with CSIR-Institute of Genomics andIntegrative Biology to produce CRISPR based COVID test kits. "]], "time": [["Last Updated: Jun 01, 2020, 05.10 PM IST"]], "publisher": [["PTI"]], "article": [["The Tata Group has entered into a partnership agreement with the ", "Sree Chitra Tirunal Institute", " for ", "Medical Sciences", " and Technology (SCTIMST), an institute of national importance, for commercial production of ", "COVID-19", " testing kits. The kits will be based on the futuristic RT-LAMP(Reverse Transcriptase of ", "India Loop-Mediated Amplification", ") technology, which can produce results in significantly less time, thereby increasing the throughput of labs in India, a ", "Tata Sons", " press release said. \n", "\n", " The tests are expected to get approval shortly and production will commence soon after. \n", "\n", "The tie with city-based SCTIMST follows Tata Sons partnership with CSIR-Institute of Genomics andIntegrative Biology to produce CRISPR based COVID test kits. \n", "\n", " The 'ChitraGene LAMP-N' test uses an isothermal setup to create copies of viral DNA for detection, whichsignificantly reduces the complexity of overall process compared to the prevalent Real Time PCRtechnology. \n", "\n", " Besides, the test also uses proprietary magnetic nanoparticle-based RNAextraction, which gives highly purified and concentrated level of RNA from the swab sample,the release said. \n", "\n", " Commenting on the tie-up, Banmali Agrawala, President - Infrastructure and Defence & Aerospace, Tata Sons, said testing was a crucial part in the fight against COVID-19 as early detection and treatmentarrests the spread of the infection. \n", "\n", " \"With more and more tests being conducted, the demand for testing kits is growing. \n", "\n", " Our association with Sree Chitra Tirunal Institute is a significant step in ourefforts to encourage indigenous production of second generation testing kits which enhances speed of testing and ease of handling,\" he said. \n", "\n", " The mass production of RT-Lamp- based COVID-19 testing kits with the active support of the Tata Group will be a significant milestone for the Institute,said Dr V K Saraswat, Member ", "Niti Aayog", " and President, Sree Chitra Institute. \n", "\n", " \"Development of a novel, inexpensive, faster, confirmatory test for the diagnosis of COVID-19 by Sree Chitra in a record time is a compelling example of how a creative team of scientists,clinicians and industry working together seamlessly can leverage knowledge and infrastructure to make relevant breakthroughs,\" said Prof Ashutosh Sharma, Secretary, DST. \n", "\n", " The SCTIMST, under the Department of Science and Technology,has a mission to become a global leader in Research and Development of affordablemedical technologies and advanced super speciality medical services, the release added.\n", "\n"]], "tags": ["covid 19 testing kits", "Sree Chitra Tirunal Institute", "Tata Sons", "Niti Aayog", "Tata Motors", "Medical Sciences"]},
{"heading": [["India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir"]], "sub_heading": [["The approval process for remdesivir was accelerated in view of the emergency situation and the unmet need for medicines in light of the coronavirus outbreak, a source in the know of the developments told ."]], "time": [["Last Updated: Jun 02, 2020, 12.46 PM IST"]], "publisher": [["PTI"]], "article": [["New Delhi: India's drug regulator has granted US pharma giant Gilead Sciences marketing authorisation for its anti-viral drug remdesivir for \"restricted emergency use\" on hospitalised COVID-19 patients in view of the crisis posed by the pandemic. \n", "\n", "The approval process for remdesivir was accelerated in view of the emergency situation and the unmet need for medicines in light of the coronavirus outbreak, a source in the know of the developments told . \n", "\n", "The drug has been allowed for restricted emergency use for a maximum of five-day period for treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children hospitalised with severe symptoms, subject to several safeguards, the source said. \n", "\n", "\"The drug, which is administered in the form of an injection, has been approved to be sold by retail on the prescription of specialists for use in hospital or institutional set-up only. It has been approved for use for a maximum of five days as against 10 days. Extended use does not seen to have any beneficial effects based on the evidence submitted at the time of approval,\" the source told . \n", "\n", "\"The approval process for remdesivir was accelerated by invoking special provisions under the New Drug and Clinical Trial Rules, 2019, which provides for waiver of clinical trials in special circumstances,\" the source said. \n", "\n", "Gilead Sciences had on May 29 applied for marketing authorisation for remdesivir in India. The drug is being touted as a potential treatment for COVID-19. \n", "\n", "The approval was given following consultation with the subject expert committee of the Central Drugs Standard Control Organisation (CDSCO). \n", "\n", "\"The drug is given in the form of an injection and that is why it has to be administered under the supervision of a doctor in a hospital setting,\" the source said. \n", "\n", "The drug, from the Gilead's manufacturing site, would be imported by Mumbai-based ", "Klinera Global Services", ", the sources said. \n", "\n", "Gilead Sciences, the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir. \n", "\n", "The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (", "FDA", ") for the treatment of hospitalized patients with severe COVID-19, they said. \n", "\n", "Meanwhile, applications of two Indian pharmaceutical companies -- Cipla and ", "Hetero Labs", " -- seeking permission to manufacture and sell remdesivir in India is still under consideration. \n", "\n", "Gilead Sciences Inc has entered into non-exclusive licensing agreements with pharma firms, including three domestic majors Cipla, Jubilant Life Sciences and Hetero, for manufacture and distribution of remdesivir. \n", "\n", "The Indian Council of Medical Research had earlier said anti-viral medication remdesivir, which was used during the Ebola outbreak, may inhibit the SARS-CoV-2 replication and research on its efficacy in the treatment of COVID-19 is a part of the WHO's 'Solidarity Trial'. \n", "\n", "According to a recently published study in ", "the New England Journal of Medicine", ", two out of three critically ill coronavirus patients who were on oxygen support showed signs of improvement when they were administered remdesivir. \n", "\n", "All new drugs have to undergo trials before getting approval for marketing them in India. \n", "\n", "However, the New Drug and Clinical Trial Rules, 2019, provide for certain clauses, according to which the provision of waiver of local phase-III clinical trials of the drug is approved and marketed in certain countries (as notified from time to time) subject to certain conditions like national emergency or epidemics in public interest. \n", "\n", "Gilead Sciences issued a statement on Remdesivir Clinical Data on Monday, saying, \"With the latest data announced today, we now have three randomized, controlled clinical trials demonstrating that remdesivir improved clinical outcomes by several different measures.\" \n", "\n", "Results from the Phase 3 SIMPLE trial showed that when treating patients with moderate disease - those with pneumonia who do not require supplemental oxygen - a 5-day course of remdesivir led to greater clinical improvement than standard care alone, the company said. \n", "\n", " Gilead plans to submit the full data for publication in a peer-reviewed journal in the coming weeks. \n", "\n", "The placebo-controlled study conducted by the National Institute of Allergy and Infectious Diseases demonstrated that remdesivir enabled more rapid recovery and that earlier treatment improved outcomes in patients with a range of disease severity. \n", "\n", "An earlier study results showed that when treating patients with severe disease - those who require non-invasive supplemental oxygen - 5 days of remdesivir led to similar improvements as a 10-day course. \n", "\n", "\"The totality of clinical data shows that remdesivir has the potential to meaningfully benefit patients with COVID-19 and offers important hope,\" it said.\n"]], "tags": ["fda", "PLB", "Hetero Labs", "klinera global services", "The New England Journal of Medicine"]},
{"heading": [["14 vaccine candidates from India look promising: Dr Renu Swarup, Department of Biotechnology"]], "sub_heading": [["Human trials for at least 3-4 candidates are likely to begin in the next 2-6 months. Biotechnology Industry Research Investment Council (BIRAC) a public sector of Department of Biotechnology, has been at the forefront since the inception of the COVID crisis."]], "time": [["Last Updated: Jun 02, 2020, 01.55 PM IST"]], "publisher": [[", ET Bureau"]], "article": [["\n", "\n", "\n", "vaccine potentials", "\n", "Out of the various vaccines being developed globally, about 30 vaccine candidates are being developed in India. Nearly 14 being developed by industry and academia show promising leads. There are also efforts where Indian academia and industry are participating in global partnerships. Many academic and research institutes are working as part of the consortium to develop platforms for vaccines. Four of these candidates are at advanced stages of development.\n", "\n", "\n", "We are making our best efforts to expedite our home-grown vaccines. The recombinant ", "BCG", " candidate has begun with the Phase III studies in April. If the results demonstrate acceptable efficacy, this candidate has the potential to make it by the year end. Also, global collaborations are being looked at between Indian companies and global vaccine groups. We will support groups in India which have potential vaccines development plan including phase II/III studies. There are also efforts to provide an enabling ecosystem. A Rapid response regulatory framework has been notified which will facilitate speedy vaccine development through the pathway. There are also discussions with the Global key stakeholders to prepare for Global Vaccine trials in the country to enable both Indian and Global players to bring their vaccines to market early.\n", "\n", "\n", "A number of vaccine development efforts are going on in the country and have progressed well. From the various candidates from the Indian companies, around nine are in early stages of development, some five in advanced stages of development and two candidates: Serum\u2019s recombinant BCG and Cadila\u2019s ", "Mycobacterium", " candidate are in Phase III studies. Under DBT-BIRAC Consortium call, 10 vaccine proposals have been recommended for funding support. These are in different stages of development.\n", "\n", "\n", "Bharat Biotech", "rabies", "\n", "Each candidate is unique and has its own scientific merits and has its own potential. However, right now I can say that the Serum BCG candidate is in phase III studies and the trial is being supported by DBT-BIRAC COVID consortium, if it shows acceptable efficacy has the potential to be implemented by the end of the year. The DNA vaccine, Rabies platform and mRNA vaccine have their own merit and are at advanced stages\n", "\n", "\n", "\n", "Yes, besides, Serum, Cadila, Bharat Biotech and Gennova that have been named earlier, we have recently recommended funding support to CMC, Vellore, NII, New Delhi and Enzene Biosciences for efforts in vaccine development. In addition, the DBT Autonomous Institutes THSTI and ICGEB are also working on different vaccine candidates.\n", "\n", "\n", "\n", "Human trials for at least 3-4 candidates are likely to begin in the next 2-6 months. Biotechnology Industry Research Investment Council (BIRAC) a public sector of Department of Biotechnology, has been at the forefront since the inception of the COVID crisis. The COVID Research Consortium initiative that started early on in March is being facilitated at BIRAC. The focus has been on Vaccines, Therapeutics and Diagnostics. It has been central to assisting startups and connecting them to investors and investments. A fast track review mechanism for COVID-19 has also been facilitated at BIRAC to fund startups and also to find co-funding partners for fast tracking efforts for COVID solutions. BIRAC is also working towards mobilizing CSR funds through Invest India platform for COVID-19 Research Consortium. A virtual partnering platform has also been developed that aims to gather the global pharma industry to connect and help bring forward solutions against the novel ", "coronavirus", " pandemic. Regular weekly FIRST HUB sessions are also being held to provide regulatory support to startups. A special legal webinar series was also conducted on business implications of COVID-19. There has also been a major effort on indigenization of Resources to respond to the call of our Prime Minister for an Atmanirbhar Bharat. In the Diagnostic sector we today have moved from 100% Testing kit import in March to today having nearly 20 Indigenous manufacturer\u2019s and a kit manufacturing capacity of over 50 Lakh kits per month. We have also launched the Pilot N-BRIC a National Biotech Resource Indigenization Consortium which provides for indigenous resources for all product development. Today we have sufficient capacities to provide complete indigenous resources for our local kit manufacturers.\n", "\n", "\n", "\n", "Serum is the largest manufacturer of vaccines globally and has earned credibility for WHO prequalified vaccine manufacturing. We wish them all the best for their collaboration with Oxford. They have announced that they will be manufacturing this vaccine; we will have to wait to see the results of the trial\n", "\n", "\n", "We are all optimistic and hope that if all goes well, we should have vaccine in the next 12-18 months. This is the situation globally as well. Our Scientists are working very hard.\n", "\n"]], "tags": ["pharmaceutical industry", "Mycobacterium", "vaccine potentials", "BCG", "rabies", "coronavirus", "Bharat Biotech"]},
{"heading": [["Strides Pharma gets USFDA nod for generic ointment to treat skin conditions"]], "sub_heading": [["Strides Pharma Science on Tuesday said it has received US health regulator's approval for its generic version of triamcinolone acetonide ointment used for treatment of various skin conditions. "]], "time": [["Last Updated: Jun 02, 2020, 12.54 PM IST"]], "publisher": [["PTI"]], "article": [["Strides Pharma Science on Tuesday said it has received US health regulator's approval for its generic version of ", "triamcinolone acetonide ointment", " used for treatment of various skin conditions. The approval is granted to the company's step-down wholly owned subsidiary, ", "Strides Pharma Global", ", Singapore, by the United States Food and Drug Administration (", "USFDA", ") for triamcinolone acetonide ointment ", "USP", ", 0.05 per cent, Strides Pharma Science said in a regulatory filing. \n", "\n", " \"The product is part of the niche and small volume product portfolio with limited competition in the US market,\" it added. Citing IQVIA data, the company said the US market for triamcinolone acetonide ointment USP, 0.05 per cent, is approximately USD 15 million. \n", "\n", " \"The product will be manufactured at the company's flagship facility at ", "Bengaluru", " and will be marketed by Strides Pharma in the US market,\" it added. \n", "\n", " The company has 124 cumulative abbreviated new drug application filings with USFDA of which 86 have been approved and 38 are pending clearance.\n"]], "tags": ["Strides Pharma Global", "triamcinolone acetonide ointment", "Bengaluru", "USFDA", "USP"]},
{"heading": [["COVID-19: 16 companies get funds for R&D work"]], "sub_heading": [[" The department of biotechnology has granted funds to 16 companies for developing drugs, vaccines and devices to fight the Covid-19 pandemic as India looks to speed up the process of tackling the disease."]], "time": [["Last Updated: Apr 22, 2020, 07.47 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["MUMBAI: The department of ", "biotechnology", " has granted funds to 16 companies for developing drugs, vaccines and devices to fight the Covid-19 pandemic as India looks to speed up the process of tackling the disease. People aware of the development said it is to the tune of \u20b950 crore to \u20b9200 crore.\n", "\n", "Zydus Cadila and ", "Bharat Biotech", " received funds for developing a vaccine for SARS-CoV-2, which causes Covid-19. Cadila is working on a DNA vaccine, while Bharat Biotech in Hyderabad is using the inactivated rabies vector platform. The DBT granted funds to Serum Institute of India to scale up the phase 3 human trials of a recombinant BCG vaccine and to ", "National Institute of Immunology", " for development of a novel vaccine evaluation platform. \n", "\n", "The department received over 500 applications in response to its call for proposals from companies working on vaccines and drugs against Covid-19 in early February. \n", "\n"]], "tags": ["biotechnology", "covid impact", "ppes", "virus vaccine india", "Bharat Biotech", "National Institute of Immunology"]},
{"heading": [["Avoid use of antibody tests for now: ICMR"]], "sub_heading": [[" The Indian Council of Medical Research on Tuesday advised states not to use the new rapid antibody test for Covid-19 from China till further notice after reports emerged that the kits are faulty. \u201cThe kits will be tested and validated in the field by our teams."]], "time": [["Last Updated: Apr 22, 2020, 07.33 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["NEW DELHI: The Indian Council of Medical Research on Tuesday advised states not to use the new rapid antibody test for Covid-19 from ", "China", " till further notice after reports emerged that the kits are faulty. \n", "\n", "\u201cThe kits will be tested and validated in the field by our teams. We will issue an advisory in two days,\u201d ", "ICMR", "\u2019s head of epidemiology and communicable diseases Raman R Gangakhedkar said. \u201cIf problems are detected in batches, we will tell the companies for replacement,\" he said.\n", "\n", "The Chinese companies that had dispatched the kits defended their product, saying they did not receive any complaints from other countries where they supplied the same kits.\n", "\n", "India had last Thursday received 500,000 rapid antibody testing kits from Guangzhou Wondfo Biotech and Zhuhai Livzon Diagnostics. Officials from the two Chinese firms, who did not wish to be named due to the sensitivity of the development, denied that their product could be faulty. They said perhaps field staff who used it did not use it properly. \n", "\n", " ICMR had procured kits to check presence of antibodies in people\u2019s blood. However, Gangakhedkar has said they have got a complaint of less detection from one state.\n", "\n"]], "tags": ["China", "antibody tests", "ppes", "ICMR", "virus testing india"]},
{"heading": [["ICMR to fund research in \u2018immunology\u2019 cure"]], "sub_heading": [["The ICMR has asked research institutions including hospitals to participate in the funding round and it expects research activities to take off by June. "]], "time": [["Last Updated: Apr 23, 2020, 07.49 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["MUMBAI: The Indian Council of Medical Research (ICMR) will fast-track funding proposals that look at immunology approaches to treat Covid-19, a move to fill the research gap in India to fight the ", "coronavirus", " outbreak. The ", "ICMR", " has asked research institutions including hospitals to participate in the funding round and it expects research activities to take off by June. \n", "\n", " \u201cAs the disease counts rise in India, it is of utmost importance that we understand the disease process better, identify at-risk population and develop advanced immunomodulatory therapeutics to treat the severe forms,\u201d said Geeta Jotwani, the scientist in charge of this programme.\n", "\n", "The funding call will look at four criteria of research proposals from the immunology field: cell-based approaches for prevention or treatment of Covid-19, use of biologics or small molecule-based therapy including vaccines, ", "immunogenetics", " and molecular epidemiology and new diagnostics tests. The proposed study should not be of more than 24 months. \n", "\n", "For cell-based therapies, the proposals may look at new genetic or non-genetic modifications of immune cells where the research focuses on aspects such as viral infection and immune response to the disease. \n", "\n", "The biologics side of the research should look at aspects such as antibodies, recombinant proteins or targeted therapies. \n", "\n", "Through the genetic study research, the ICMR is looking for research that explores why certain diseases like diabetes, lung diseases and cancer lead to higher risk of morbidity and mortality through Covid-19. \n", "\n", "On the diagnostic research side, the idea is to find new tools that address the issues of confusion regarding efficacy of ", "antibody", " kits. The diagnostic approach, the ICMR says, would have to describe the novelty in terms of process, sensitivity, specificity, strength of risk stratification and scalability.\n", "\n", "Meanwhile, HealthCare Global has received permission from the drug controller to conduct the plasma therapy trial on Covid patients. \n", "\n", "\n", "\n", " \n", "\n"]], "tags": ["AntiBody", "vaccine india", "coronavirus", "Immunogenetics", "ICMR"]},
{"heading": [["FDA approves first in-home test for coronavirus"]], "sub_heading": [["Patients will swab their own nose using a testing kit sent by the company and will mail it in an insulated package back to the company. "]], "time": [["Last Updated: Apr 22, 2020, 07.57 AM IST"]], "publisher": [["New York Times"]], "article": [["The Food and Drug Administration on Tuesday said it had granted emergency clearance to the first in-home test for the coronavirus, a nasal swab kit that will be sold by ", "LabCorp", ".\n", "\n", "The agency said that LabCorp had submitted data showing the home test is as safe and accurate as a ", "sample collection", " at a doctor\u2019s office, hospital or other testing site.\n", "\n", "\u201cWith this action, there is now a convenient and reliable option for patient sample collection from the comfort and safety of their home,\u201d Dr. Stephen M. Hahn, the ", "FDA", " commissioner, said in a statement.\n", "\n", "Patients will swab their own nose using a testing kit sent by the company and will mail it in an insulated package back to the company. The Pixel by LabCorp COVID-19 test will be available to consumers in most states, with a doctor\u2019s order, the agency said.\n", "\n", "LabCorp said that it would first make the tests available to health care workers and emergency workers who may have been exposed to COVID-19 or be symptomatic, and that it would be making the self-collection kits available to consumers \u201cin the coming weeks.\u201d The company also noted that because the tests are done by consumers in their own home, it would cut down on the demand for masks and other protective equipment that is usually needed to collect testing specimens.\n", "\n", "The company said the test will cost $119. Consumers will have to pay out of pocket for the test, a company spokesman said, and ask their insurer for reimbursement. The Trump administration has repeatedly said that diagnostic tests for the coronavirus will be covered so that consumers don\u2019t have to foot the bill.\n", "\n", "At a moment when governors across the country say their states are facing a shortage of tests, and companies like CVS and Walmart are setting up drive-through testing centers in parking lots, the arrival of kits that let people collect their own nasal specimens at home has the potential to open up testing to a wider audience.\n", "\n", "Medical experts said the home-swabbing tests could increase convenience for consumers \u2014 and reduce the need for people to go to medical offices where they might inadvertently expose health providers and other patients to the infection.\n", "\n"]], "tags": ["virus death toll", "fda", "sample collection", "virus testing", "LabCorp"]},
{"heading": [["ICMR to give verdict on antibody kits next week"]], "sub_heading": [[" The Indian Council of Medical Research has started analysing results from the evaluation of antibody test kits imported from China and will come out with its conclusions on their efficacy early next week, a senior government official told ET."]], "time": [["Last Updated: Apr 24, 2020, 08.46 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["NEW DELHI: The Indian Council of Medical Research has started analysing results from the evaluation of antibody test kits imported from China and will come out with its conclusions on their efficacy early next week, a senior government official told ET.\n", "\n", "The ", "ICMR", "\u2019s decision will determine whether the antibody test kits can be used in the country and if India should procure more of them, the official added.\n", "\n", "Expert teams were sent to eight states following complaints that the test kits sent to them had generated inaccurate results.\n", "\n", "\u201cThe teams have initiated a study in eight states and the results on the validity of antibody test kits will be out soon. The results of this will influence the further purchase of kits,\u201d another government official said.\n", "\n", "The official said the kits were procured at the request of the states. The ICMR had also decided to use these kits to check the rate of positivity and the prevalence of the infection in various clusters. The official said this surveillance plan will proceed only after establishing the validity of the kits.\n", "\n", "The ICMR had halted antibody testing for two days on Tuesday after receiving complaints about inaccuracies. On Wednesday, it reiterated that the must follow the \u201cprescribed protocol\u201d and use the tests only as a surveillance tool for Covid-19 cases.\n", "\n", "\u201cThese test results are also dependent on field conditions,\u201d it said in a letter to the states on Wednesday.\n", "\n", "\u201cThe teams will see how the states have been using them because a lot also depends on temperature conditions,\u201d added the official.\n", "\n", "The ICMR said it will continue to collect data from the states to assess the scope and extent of the utility of these rapid antibody tests in various field conditions and will issue updated advisories on a regular basis.\n", "\n", "\u201cln view of this, states are advised to follow the prescribed protocol for these tests and use it for the purposes for which these are meant. It is reiterated that to contain ", "coronavirus", " infection, RT-PCR (reverse transcription polymerase chain reaction) tests must be continued vigorously as the principal diagnostic tests,\u201d additional director general GS Toteja said in the letter.\n", "\n"]], "tags": ["Health ministry", "india testing", "covid death toll", "coronavirus", "antibody testkits", "ICMR"]},
{"heading": [["Mazumdar-Shaw recognised among world's top 20 inspirational leaders in Biopharma"]], "sub_heading": [["Biocon Executive Chairperson Kiran Mazumdar-Shaw has been recognised for her contribution to the world of medicine as an entrepreneur and innovative business leader, the Bengaluru-headquartered biopharmaceuticals company said in a statement. "]], "time": [["Last Updated: Apr 28, 2020, 07.00 PM IST"]], "publisher": [["ET Bureau"]], "article": [["Bengaluru: ", "Kiran Mazumdar-Shaw", ", chairperson of ", "Biocon", ", has been recognized as one of the world\u2019s top 20 inspirational leaders in ", "biopharmaceuticals", " in The Medicine Maker \u2018Power List 2020\u2019 for her contribution to the world of medicine as an entrepreneur and innovative business leader. \n", "\n", "The Power list 2020 presents top 20 inspirational medicine makers from the world of small molecules, biopharmaceuticals, and advanced medicine. \n", "\n", "\u201cIt\u2019s indeed an honour to be featured on the \u2018", "Medicine Maker Power List", "\u2019 alongside G V Prasad and other remarkable and inspirational individuals whose work has positively influenced the fields of small molecules, biopharmaceuticals and advanced medicine,\u201d said Mazumdar-Shaw. \n", "\n", "\u201cAt a time when humanity is threatened by a deadly viral pandemic, the world is looking at the medical sciences to get us through the crisis. The medical science community has risen to the challenge, sharing knowledge of potential treatments, coordinating clinical trials, developing new models of cooperation, and publishing findings immediately to tackle the COVID-19 pandemic. This is the spirit that those on the Medicine Maker Power List epitomize and I feel privileged to be recognised for my efforts in making the world a healthier place,\u201d she added.\n", "\n"]], "tags": ["MazumdarShaw", "Bengaluru", "biopharmaceuticals", "medicine maker power list", "biocon"]},
{"heading": [["As cotton swabs run out, ICMR looks at polyester"]], "sub_heading": [["Until last month, polyester swabs were not manufactured in India and were imported from the US or China. With global demand for this product going up, it became difficult and more expensive to buy these swabs from either country."]], "time": [["Last Updated: May 07, 2020, 08.17 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["NEW DELHI: The Indian Council of Medical Research (", "ICMR", ") has been evaluating the effectiveness of polyester swabs for Covid-19 test kits amid a shortage of cotton swabs.\n", "\n", "Nasal and throat swabs are used to detect the presence of the coronavirus and the shortage of cotton swabs could lead to a slowdown in the testing process in India. The government and companies are looking at other options and polyester swabs are being considered a suitable alternative.\n", "\n", "A study by an infectious disease physician in the Seattle area found that Covid-19 specimens can be successfully taken with polyester swabs. The US Food and Drug Administration changed its guidelines recently to allow polyester swabs, with samples stored in saline, to be used for testing.\n", "\n", "\n", "\n", "\n", "The ICMR has validated polyester swabs made by Suparshva Swabs, said Rahul Jain, a partner at the New Delhi-based company that makes Tulips-branded products. ICMR\u2019s validation came through on Tuesday, Jain said.\n", "\n", "Until last month, polyester swabs were not manufactured in India and were imported from the US or China. With global demand for this product going up, it became difficult and more expensive to buy these swabs from either country.\n", "\n", "\u201cIndia was facing a shortage as it is an imported material. They were not only 10 times more expensive but there was a shortage, too,\u201d said Jain. ICMR approached the company last month to make polyester swabs, Jain said.\n", "\n", "\u201cWe changed our production line to make the requisite product as per the ICMR guidelines. With the approval coming in, supply will start to the VTM (viral transport medium) manufacturers,\u201d he said. The company produces 2 million polyester swabs a week. India uses the reverse transcription polymerase chain reaction (RT-PCR) process to detect the presence of the coronavirus and plans to increase its testing capacity to 500,000 a day by July.\n", "\n"]], "tags": ["testing india", "antibody test kits", "india covid updates", "coton swabs", "ICMR"]},
{"heading": [["Diagnostic centres see increase in requests to do Covid-19 tests"]], "sub_heading": [["Private diagnostic centres and hospital laboratories have seen a 50% increase in the number of requests for RT-PCR tests within a day of home ministry\u2019s new guidelines for opening up lockdown. "]], "time": [["Last Updated: Jun 01, 2020, 06.41 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["NEW DELHI:As India gradually opens up malls, restaurants and offices, private companies, hotel owners, airlines, air travellers and security agencies are rushing to ", "private diagnostic centres", " to get Covid-19 all-clear for employees through a ", "confirmatory test", ".\n", "\n", "Private diagnostic centres and ", "hospital laboratories", " have seen a 50% increase in the number of requests for ", "RT-PCR", " tests within a day of home ministry\u2019s ", "new guidelines", " for opening up lockdown. ET contacted 10 private laboratories and two private hospital chains. All confirmed that a majority of the queries have come from hotel owners, hospitality sector and airlines. \n", "\n", "Dr Arjun Dang, CEO of Dr Dangs laboratories, said, \u201cWe have got a number of emails from private companies requesting us to test their employees so that they can resume work. There are very strict guidelines for conducting RT-PCR tests so we have not been able to conduct these tests.\u201d Dr Dang confirmed that with the decision to open up malls, hotels and restraurants, there has been an increased demand from there as well. \n", "\n", "Max Healthcare", " also confirmed they had been receiving requests from corporate sector to conduct tests. An order of Uttar Pradesh government dated May 4 has come handy for several companies based out of ", "Noida and Greater Noida", " to get their employees tested. The order had allowed a company to get 5% of their employees randomly tested for Covid-19. Though with the new set of guidelines in place starting June 8, this order would not hold. \n", "\n", "Airlines and air travellers have also added to the rush in getting RT-PCR tests. Air travellers need a negative RT-PCR test 48 hours before they travel. \u201cThis has now added to demand for tests,\u201d said Dr Dang. \n", "\n"]], "tags": ["new guidelines", "private diagnostic centres", "hospital laboratories", "Noida and Greater Noida", "Max Healthcare", "confirmatory test"]},
{"heading": [["Project CARD to push local production of testing kits"]], "sub_heading": [[" Niti Aayog and the Department of Biotechnology have launched the Consortium for Affordable & Rapid Diagnostics (CARD) to scale up India\u2019s capacity to make coronavirus testing kits. The move comes after India faced quality issues with Chinese-made antibody testing kits."]], "time": [["Last Updated: May 07, 2020, 07.36 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["MUMBAI: Niti Aayog and the ", "Department of Biotechnology", " have launched the Consortium for Affordable & ", "Rapid Diagnostics", " (CARD) to scale up India\u2019s capacity to make ", "coronavirus", " testing kits.\n", "\n", "The move comes after India faced quality issues with Chinese-made antibody testing kits, which are used for disease surveillance and to find out how many people have developed immunity to a disease.\n", "\n", "Project CARD\u2019s first goal is to roll out at least 10 million rapid antibody tests for Covid-19 by July. Additionally, capacity will be expanded to make reverse transcription polymerase chain reaction (RT-PCR) and other paper-based tests for Covid-19 in the country.\n", "\n", "\u201cWhile India is strong in biopharmaceuticals sector and recognised as a global powerhouse, its domestic capacity for diagnostics manufacturing has lagged behind. To address this gap, this platform will synchronise all stakeholders for a common, urgent goal towards accelerating Covid-19 diagnostics in India,\u201d Anna Roy, senior advisor at Niti Aayog, told ET.\n", "\n", "Trivetron Healthcare, Syngene International and Reliance Industries are three companies that are working on ", "antibody test kits", " in India and they will get the initial support in terms of procurement and availability of testing facilities to manufacture the kits.\n", "\n", "\u201cThe private and public sectors will collaborate to set up test delivery and administering systems in Covid-19 hotspots, leveraging existing infrastructure, augmented by new-age technology,\u201d Roy said.\n", "\n", "Globally, antibody tests have become vital for governments to check the spread and decide on future course of action. India has looked to buy the test kits from China, South Korea, Switzerland and the US.\n", "\n"]], "tags": ["antibody test kits", "india covid updates", "department of biotechnology", "coronavirus", "rapid diagnostics", "ICMR"]},
{"heading": [["Biocon gets establishment inspection report from USFDA for Bengaluru plant"]], "sub_heading": [["The EIR has been closed with a voluntary action indicated (VAI) classification for the observations, it added. As per the USFDA, a VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action. "]], "time": [["Last Updated: May 08, 2020, 01.47 PM IST"]], "publisher": [["PTI"]], "article": [["NEW DELHI: Biotechnology major ", "Biocon", " on Friday said it has received the establishment inspection report (EIR) from the US health regulator for its facility at Bengaluru. The company has received the EIR from the ", "US Food and Drug Administration", " (", "USFDA", ") for the pre-approval and good manufacturing practice inspection of its small molecules ", "active pharmaceutical ingredient", " (API) manufacturing facility at ", "Biocon Park SEZ", ", Bengaluru, it said in a filing to BSE. \n", "\n", " The inspection of the plant was conducted between January 20 and January 24, 2020, it added. \n", "\n", " \"At the conclusion of the inspection the agency had issued a Form 483, with five observations, which are being addressed by the company,\" Biocon said. \n", "\n", " The EIR has been closed with a voluntary action indicated (VAI) classification for the observations, it added. \n", "\n", " As per the USFDA, a VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action. \n", "\n", " \"We remain committed to global standards of quality and compliance,\" a company spokesperson said. \n", "\n", " Shares of Biocon were trading at Rs 357.65 per scrip on BSE, up 2.29 per cent from their previous close.\n"]], "tags": ["us food and drug administration", "USFDA", "biocon park sez", "API manufacturing", "active pharmaceutical ingredient", "biocon"]},
{"heading": [["Bharat Bio leads CSIR project to develop human antibodies"]], "sub_heading": [["This programme brings together academia \u2014 National Centre for Cell Science, Indian Institute of Technology, Indore, and industry \u2013 PredOmix Technologies and Bharat Biotech, in a collaborative mode for a public health emergency."]], "time": [["Last Updated: May 09, 2020, 09.44 AM IST"]], "publisher": [["ET Bureau"]], "article": [["HYDERABAD: Global vaccine manufacturer ", "Bharat Biotech", " has received sanction from the Council of Scientific and Industrial Research (CSIR) to lead a project to develop human monoclonal antibodies as therapy for Covid-19 infections.\n", "\n", "This programme brings together academia \u2014 National Centre for Cell Science, Indian Institute of Technology, Indore, and industry \u2013 PredOmix Technologies and Bharat Biotech, in a collaborative mode for a public health emergency.\n", "\n", "Though efforts were underway for the development of drugs and ", "vaccines", " for controlling the Covid-19 pandemic, they were slow with expensive processes coupled with uncertainties, Bharat Biotech said in a press release on Friday.\n", "\n", "Saying that an alternate therapeutic regimen for early deployment was critical, the Hyderabad-headquartered vaccine maker said, \u201cThe present project aims at such an alternate therapeutic regimen by generating highly effective and specific human monoclonal antibodies that are capable of neutralizing the SARS-CoV2 virus.\u201d Such virus-neutralising antibodies can block the spread of infection by binding with the virus and rendering it ineffective. ", "Monoclonal antibody therapy", " is a highly effective and safe method, it said. \u201cThe purpose of vaccination is to protect the healthy against future infections and it alone may not provide the complete solution. We feel the monoclonal ", "antibody", " therapy will provide a viable option,\u201d said Dr Krishna Ella, CMD of Bharat Biotech.\n", "\n", "Israel and Netherlands recently announced development of virus-neutralising antibodies. However, the approach of CSIR\u2019s project was to develop a powerful cocktail of neutralising antibodies that can also simultaneously block mutational variants of the virus, said Dr Ella.\n", "\n", "\u201cWe are fast-tracking the development process, to make the antibodies available within the next six months, and thus improve the treatment efficacy.\u201d\n", "\n", "Bharat Biotech, which has a track record in identifying potential viral threats, has so far developed 10 different viral vaccines and has till date delivered more than 5 billion doses of viral vaccines, including anti Rabies vaccines.\n", "\n"]], "tags": ["AntiBody", "Vaccines", "monoclonal antibody therapy", "covid updates", "Bharat Biotech"]},
{"heading": [["Government picks IIT, Bennett University proposals in war on Covid"]], "sub_heading": [["In order to urgently develop \u201csafe and effective biomedical solutions\u201d against Covid-19, the department of biotechnology (DBT) under science ministry has recommended 70 proposals from different institutions, including several IITs, JNU and Bennett University, for funding. These proposals are related to the development of vaccines, devices, diagnostics, therapeutics and other technological interventions."]], "time": [["Last Updated: May 11, 2020, 10.48 AM IST"]], "publisher": [[", TNN"]], "article": [["NEW DELHI: In order to urgently develop \u201csafe and effective biomedical solutions\u201d against ", "Covid-19", ", the department of biotechnology (DBT) under science ministry has recommended 70 proposals from different institutions, including several IITs, ", "JNU", " and ", "Bennett University", ", for funding. These proposals are related to the development of vaccines, devices, diagnostics, therapeutics and other technological interventions.\n", "\n", "The shortlisted proposals include 10 vaccines candidates, 34 diagnostics products or scale-up facilities, 10 therapeutics options, two proposals on drug repurposing and 14 projects related to preventive interventions.\n", "\n", "\u201cThe Bennett University\u2019s proposal is related to diagnostics (Fluorescence and Electrochemistry Mediated Rapid Detection of SARS-CoV-2 Nucleic Acid) which may take care of testing needs of the country,\u201d said an official in science ministry.\n", "\n", "He said the DBT and its ", "Biotechnology Industry Research Assistance", " Council (BIRAC) approved it along with other proposals after evaluating various proposals from different academic institutions, keeping long term need for diagnostics requirement in mind.\n", "\n", "\u201cThis is being done to ensure complete indigenization of Covid-19 diagnostics. Under this support, academic institutes will receive financial support to ensure that there is no shortage of indigenous diagnostic kits in the near future,\u201d he said.\n", "\n", "Other proposals which got the DBT-BIRAC\u2018s nod under diagnostics category include portable microfluidics embedded on-chip RT-PCR and microelectrode array coupled point-of-care optoelectronic device for large scale screening of JNU; development and evaluation of aptamer-based lateral flow assay kit for detection of SARS-CoV-2 detection of IIT Delhi and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) based diagnosis of Covid-19 using paper microfluidics form IIT Guwahati. \n", "\n", "\u201cMost of the proposals are ready for immediate deployment,\u201d said the official.\n", "\n", "These are in addition to what the CSIR\u2019s labs have done on the rapid testing front including the development of \u2018Feluda\u2019 - a paper-based test strip for Covid-19 which is named after fictional detective created by Satyajit Ray. The CSIR had last week joined hands with the TATA Sons for its deployment and widespread use for rapid mass testing on the ground as early as this month-end.\n", "\n", "On the vaccine development front, the DBT has identified institutes which will provide animal models for testing pre-clinical efficacy and also make available neutralization assays.\n", "\n", "\u201cIIT Indore will produce Pseudovirus SARS-CoV-2 which can be used for the development of in-vitro assays. Enzene biosciences limited will make available Spike protein and Receptor Binding Domain protein in large quantities to vaccine and diagnostic companies as a reagent,\u201d said a statement from the ministry.\n", "\n", "It said, \u201cThe portfolio of vaccine candidates has further been enhanced by providing support for the development of next-generation mRNA vaccine candidate by Gennova and also separately to CMC, Vellore for a lipid encapsulated mRNA based vaccine.\u201d\n", "\n", "The DBT has also launched a National Biomedical Resource Indigenization Consortium (NBRIC) in a Public-Private Partnership (PPP) model to foster indigenous innovation focused on developing reagents and resources for diagnostics, vaccines and therapeutics for Covid-19.\n", "\n"]], "tags": ["Bennett university", "Indian Institute of Technology Guwahati", "biotechnology industry research assistance", "JNU", "covid", "Corona Vaccine", "coronavirus vaccine", "corona vaccine news"]},
{"heading": [["Experimental COVID-19 test detects coronavirus in 10 minutes: Study"]], "sub_heading": [["According to the study, published in the journal ACS Nano, the test uses a simple assay containing gold nanoparticles to detect a colour change when the virus is present."]], "time": [["Last Updated: May 30, 2020, 06.30 PM IST"]], "publisher": [["PTI"]], "article": [["Washington: Scientists have developed an ", "experimental diagnostic test", " for COVID-19 that can visually detect the presence of the novel ", "coronavirus", " in 10 minutes, an advance that may lead expansion of testing for the virus across the world. \n", "\n", " According to the study, published in the journal ACS Nano, the test uses a simple assay containing gold nanoparticles to detect a colour change when the virus is present. \n", "\n", " The researchers from the ", "University of Maryland", " School of Medicine (UMSOM) said the test does not require the use of any advanced laboratory techniques, such as those commonly used to make multiple copies of the viral genetic material for analysis. \n", "\n", " \"Based on our preliminary results, we believe this promising new test may detect ", "RNA material", " from the virus as early as the first day of infection,\" said study lead author Dipanjan Pan from UMSOM. \n", "\n", " However, Pan said additional studies are needed to validate whether the test can achieve this reliably. \n", "\n", " In this experimental test, once a nasal swab or ", "saliva sample", " is obtained from a patient, the RNA is extracted from the sample via a simple process that takes about 10 minutes, the study noted. \n", "\n", " According to the scientists, the test uses a highly specific molecule attached to gold nanoparticles to detect a particular protein that is part of the genetic sequence unique to the novel coronavirus. \n", "\n", " When this ", "biosensor", " binds to the gene sequence, the study said the gold nanoparticles respond by turning the liquid reagent from purple to blue. \n", "\n", " \"The accuracy of any COVID-19 test is based on being able to reliably detect any virus. This means it does not give a false negative result if the virus actually is present, nor a false positive result if the virus is not present,\" Pan explained. \n", "\n", " He said many of the diagnostic tests currently on the market cannot detect the virus until several days after infection. \n", "\n", " \"For this reason, they have a significant rate of false negative results,\" he added. \n", "\n", " The researchers believe that the RNA-based test is very promising in terms of detecting the virus. \n", "\n", " Although more clinical studies are needed to ascertain the effectiveness of the test, they said it could be far less expensive to produce and process than a standard COVID-19 lab test. \n", "\n", " It does not require laboratory equipment or trained personnel to run the test and analyse the results, the scientists said. \n", "\n", " They added that it could potentially be used in daycare centers, nursing homes, college campuses, and work places as a surveillance technique to monitor any resurgence of infections.\n"]], "tags": ["University of Maryland", "coronavirus", "saliva sample", "DNA sequencing", "biosensor", "Scientist", "University of Washington", "rna material", "Statistical hypothesis testing", "experimental diagnostic test"]},
{"heading": [["Stimulus package can help Biotech sector become self-reliant"]], "sub_heading": [["Kiran Mazumdar-Shaw said that the world is waiting for a vaccine for COVID-19 but till the time it is developed, there is a need to conduct tests and build a treatment regime to save lives. Indian biotech sector worked quickly and came out with indigenous test kits."]], "time": [["Last Updated: May 16, 2020, 03.35 PM IST"]], "publisher": [["ET Bureau"]], "article": [["NEW: Biotechnology is an asset heavy industry, said ", "Kiran Mazumdar-Shaw", ", executive chairperson, ", "Biocon", " at a webinar on \u201cWonder Women in Frontline Biotech: India Leading the Race for Covid Cure\u201d organized by ", "FICCI", " Ladies Organization (FLO), the women\u2019s wing of the apex industry body, FICCI. She added that it would be beneficial if the government provided a stimulus package as this is a huge opportunity for the ", "biotech", " sector to become self-reliant, according to a release.\n", "\n", "Mazumdar-Shaw said that the world is waiting for a vaccine for COVID-19 but till the time it is developed, there is a need to conduct tests and build a treatment regime to save lives. Indian biotech sector worked quickly and came out with indigenous test kits. Today, more than 200,000 tests can be conducted using ", "RT-PCR kits", " and soon over a million tests can be conducted using indigenous test kits, she added. \n", "\n", "She further pointed out that this is the time for all technologies to converge and biotech\u2019s role is very vital in this. COVID-19 is an emergency, the government needs to step up for such emergencies and look at long term planning, she added.\n", "\n", "Speaking on how biotechnology companies are contributing towards developing a vaccine for COVID-19, Suchitra Ella, joint managing director, ", "Bharat Biotech", ", said that broad-based approach has been adopted for developing treatment therapies for COVID-19. She added that the world is together in this crisis and the need is to cut across barriers for public health. \n", "\n", "Mahima Datla, managing director, Biological E Limited said assuming that a vaccine is successful, it is important to understand that investment is needed to scale it up. Going from lab success to making 100 million doses is not trivial. She underlined that there is a need for cohesive funding for product development.\n", "\n", "Underlining that biotechnology is leading the charge and actively contributing towards research efforts to find a vaccine to combat the virus, Jahnabi Phookan, president elect, FICCI FLO, said, \u201cIndia\u2019s biotechnology industry is working towards finding the next generation cure for COVID-19. Today, when we are in the midst of an unprecedented public health crisis, Covid-19 has put the entire globe into a slowdown but it looks like India handled the situation relatively well than other big and developed countries. We feel happy that our biotechnology industry is making sincere efforts towards finding solutions to tackle the pandemic with vaccines and medicines with the help from leading biotechnology companies in India.\u201d\n", "\n", "\n"]], "tags": ["ficci", "biocon", "Bharat Biotech", "biotech"]},
{"heading": [["Vaccine to prevent COVID-19 will take long time to be ready: Kiran Mazumdar-Shaw"]], "sub_heading": [["She was speaking at a webinar on 'Pharma and Healthcare' Engaging With Customers in Uncertain Times; Business Model Post-COVID-19', organised by CorpGini."]], "time": [["Last Updated: May 30, 2020, 08.17 PM IST"]], "publisher": [["PTI"]], "article": [["A safe Vaccine to prevent COVID-19 could take a very long time to be ready, so there is a need to deal with the pandemic for next few years and invest more in healthcare, ", "Biocon", " Executive Chairperson ", "Kiran Mazumdar-Shaw", " said on Saturday. She was speaking at a webinar on 'Pharma and ", "Healthcare", "'s New Normal: Engaging With Customers in Uncertain Times; Business Model Post-COVID-19', organised by CorpGini. \n", "\n", "\"...We believe that it will take a very long time before you can actually have a safe vaccine that can be accessible to the entire country. We must understand that vaccine development is a very complex process. Shortest time taken for any vaccine is not less than 4 years,\" Mazumdar-Shaw said. \n", "\n", "Trying to develop vaccine in less than a year is a very daunting and almost impossible task. Vaccine development involves a large number of processes to establish the safety, efficacy and endurance of the vaccine, she added. \n", "\n", "\"We need to deal with this pandemic for the next few years before we really get a reliable vaccine... We need to invest much more in healthcare. If this pandemic has exposed one ugly truth about every country, not just India, it is about the appalling state of public and primary healthcare, appalling state of under investing in healthcare,\" Mazumdar-Shaw said. \n", "\n", "Healthcare is a capital intensive sector, it is a skill intensive sector, it is a employment generation sector, she added. \n", "\n", "\"There needs to be a very systematic data led approach to see how can we deal with the infection and keep people safe,\" Mazumdar-Shaw said. \n", "\n", "This is one opportunity for us to invest in healthcare infrastructure, because this what will save India and the world, she added. \n", "\n", "In similar vein, ", "Apollo Hospitals", " MD Suneeta Reddy said: \"This pandemic has clearly shown us the need for medical infrastructure. There needs to be an investment in healthcare, not only in infrastructure but also in skilling\". \n", "\n", "Impetus given to the IT sector needs to be given to the healthcare sector to create additional infrastructure, she added. \n", "\n", "We hope the government considers healthcare as next IT sector, Reddy said.\n"]], "tags": ["coronavirus", "biocon", "Apollo Hospitals", "healthcare"]},
{"heading": [["Bharat Bio, Thomas Jefferson varsity to pursue Covid-19 vaccine candidate"]], "sub_heading": [["The vector used in this new COVID-19 vaccine under accelerated development program is a deactivated rabies vaccine that is known to produce a strong immune response and is approved for the whole population including children and pregnant women, it said."]], "time": [["Last Updated: May 20, 2020, 03.29 PM IST"]], "publisher": [["ET Bureau"]], "article": [["HYDERABAD: ", "Vaccine", " manufacturer Bharat Biotech announced signing an exclusive agreement with ", "Thomas Jefferson", " University of Philadelphia to develop a new vaccine candidate for ", "COVID-19", " invented at Jefferson. \n", "\n", "The novel vaccine was developed using an existing deactivated rabies vaccine as a vehicle for ", "coronavirus", " proteins, said the Hyderabad headquartered vaccine maker. \n", "\n", "The vector used in this new COVID-19 vaccine under accelerated development program is a deactivated rabies vaccine that is known to produce a strong immune response and is approved for the whole population including children and pregnant women, it said.\n", "\n", "In January this year, infectious diseases expert Professor Matthias Schnell\u2019s lab developed the vaccine, and has recently completed preliminary tests in animal models. According to ", "Bharat Bio", ", the vaccine showed a strong antibody response in mice receiving the vaccine, and the researchers are currently testing whether vaccinated animals are protected from SARS-CoV-2 infection with results expected in the next month.\n", "\n", "\u201cSince we know the immune system reacts to the rabies vaccine with a strong response when we add the coronavirus component, we expect to see that level of protection, and immune memory, carry over to the SARS-CoV-2 viral protein as well,\u201d saysProf. Schnell.\n", "\n", "Bharat Biotech gains exclusive rights to develop, market and deliver Jefferson\u2019s vaccine under the agreement across the world excluding countries such as USA, Europe and Japan, where Jefferson continues to seek partners. With support from India\u2019s Department of Biotechnology, Bharat Biotech aims to get into human trials as soon as December 2020.\n", "\n", "\u201cOur partnership with Bharat Biotech will accelerate our vaccine candidate through the next phases of development,\u201d said Prof Schnell, a coronavirus expert who directs The Jefferson Vaccine Institute and chairs Jefferson\u2019s Department of Microbiology and Immunology. \u201cWe will be able to complete animal testing and move to phase-I clinical trial rapidly.\u201d\n", "\n", "Bharat Biotech chef executive Dr Krishna Mohan said, \u201cBharat Biotech is pleased to collaborate with Thomas Jefferson, USA towards developing a new vaccine for COVID-19 using an inactivated rabies vector platform. We are particularly excited about this technology since the basic proof of concept has been established while using it for other pandemic infectious diseases.\u201d\n", "\n"]], "tags": ["vaccine", "bharat bio", "coronavirus", "Thomas Jefferson"]},
{"heading": [["Most private labs in Karnataka yet to ramp up Covid-19 testing"]], "sub_heading": [["Of the 62 laboratories in Karnataka, 28 are private. The state has tested 2.8 lakh samples as of May 30 and the data shows that just 1/8th of these samples were tested by private labs. "]], "time": [["Last Updated: Jun 01, 2020, 03.23 PM IST"]], "publisher": [[", ET Bureau"]], "article": [["Bengaluru: Most of the ICMR-approved ", "private labs", " in ", "Karnataka", " designated for Covid-19 test are under utilised. According to the state government, private labs, except a few, are functioning only up to 20% or less of their actual capacity.\n", "\n", "Of the 62 laboratories in Karnataka, 28 are private. The state has tested 2.8 lakh samples as of May 30 and the data shows that just 1/8th of these samples were tested by private labs. Even among the ", "government labs", ", most load is taken by four labs that have done a lakh tests put together.\n", "\n", "Private lab representatives and government officials point at multiple factors that have resulted in these labs not taking enough load.\n", "\n", "Dr CN Manjunath, nodal officer in charge of Covid labs and testing in Karnataka, said that cost factor could be one of the reasons behind private labs\u2019 reluctance to take samples from the government. \u201cThe government pays only \u20b92,200 per test whereas private individuals pay \u20b94,500. These labs may prefer to test individual samples over the government one, because of the profit margin,\u201d he said.\n", "\n", "He said that the government too prefers to test in the government-run labs and samples are routed to private labs only in case of excess backlog. \u201cMany of these private labs started only weeks ago. They may take some time to function to the full or at least 80% of their capacity,\u201d Manjunath said.\n", "\n", "People in charge of private labs, especially those attached to medical hospitals, say that labs are already under pressure to handle samples of their in-patients, hence taking samples from the government is challenging. \u201cPriority is to test samples of our patients and we test samples from the government based on availability of time and resources,\u201d said the nodal officer of a private lab attached to a hospital in Bengaluru.\n", "\n", "Also, the efficiency of standalone private labs is much higher compared to hospital labs. \u201cStandalone labs have enough RNA extractors and skilled resources. Medical colleges and hospitals that recently got ICMR approval, may not have sufficient RNA extractors,\u201d said a person in charge of a private lab that also does Covid tests.\n", "\n", "Some private labs, however, are an exception. For instance, Syngene International lab in Bengaluru has tested over 10,000 samples, all of which came from the government. \u201cWe are not charging the government for testing. The company bears the cost under corporate social responsibility. That is why we get more samples,\u201d Dr Anil K, nodal officer of Syngene lab, told ET.\n", "\n", "The state government on May 29 issued an order asking seven private labs in Bengaluru to open swab collection kiosks in the airport and railway stations to take swab samples of international and interstate passengers on arrival. \u201cIt will improve the participation of ICMR-approved private labs. Many are running at suboptimal levels,\u201d the health commissioner said.\n", "\n"]], "tags": ["Karnataka", "government labs", "coronavirus", "private labs"]},
{"heading": [["Excellent job by India in reducing COVID-19 related deaths by clamping lockdown: Indian-American doc"]], "sub_heading": [["India currently has over 1,82,00 confirmed cases of the coronavirus and 5,164 deaths, according to the Union Health Ministry. According to the World Health Organisation's COVD-19 tracker, India is the seventh-most affected nation in terms of coronavirus cases after the US, Brazil, Russia, UK, Spain and Italy."]], "time": [["Last Updated: Jun 01, 2020, 11.20 AM IST"]], "publisher": [["PTI"]], "article": [["Washington: India has done an excellent job in reducing the coronavirus-related deaths by clamping a nation-wide lockdown to combat the deadly virus that has claimed over three lakh lives globally, according to an eminent Indian-American cardiologist. \n", "\n", "India currently has over 1,82,00 confirmed cases of the coronavirus and 5,164 deaths, according to ", "the Union Health Ministry", ". \n", "\n", "According to ", "the World Health Organisation", "'s COVD-19 tracker, India is the seventh-most affected nation in terms of coronavirus cases after the US, Brazil, Russia, UK, Spain and Italy. \n", "\n", "The US is the worst-affected country in terms of cases with 1.79 million cases and over one lakh deaths, and globally over three lakh deaths have been reported and more than 6.15 million infections. \n", "\n", "\"A recent ", "Columbia University", " study that supports that death is prevented by earlier lockdowns bears the fact that ", "Narendra Modi", "'s government has done an excellent job in clamping lockdown,\" Tennessee-based Dr Indranill Basu Ray said in a statement. \n", "\n", "This modeling study showed that if New York had initiated lockdown even two weeks back than the March 3 date when the deaths were around 65,000 - it could have been reduced by 50,000, said Dr Ray, a cardiologist and cardiac electrophysiologist who has also been a Professor of medicine and public health at multiple universities in the US and India. \n", "\n", "The lockdown in India, was first clamped on March 25 and spanned for 21 days, while the second phase of the curbs began on April 15 and stretched for 19 days till May 3. The third phase of the lockdown was in effect for 14 days and ended on May 17. The fourth phase ended on May 31. \n", "\n", "The country had registered 512 coronavirus infection cases till March 24. \n", "\n", "\"My opinion for India would be to slowly open places for people that are not hotspots. Determining areas of opening can be based on multiple factors...,\" Dr Ray said. \n", "\n", "A slow and step ladder approach may also be taken with a change in course as mandated, he said, as the nation-wide lockdown in containment zones will continue till June 30 in India but extensive relaxations in a phased manner from June 8 are listed in the ", "Union Home Ministry", "'s fresh guidelines on tackling the COVID-19 pandemic issued on Saturday. \n", "\n", "While hotspots would need to be under extended lockdown but increased testing is mandatory along with isolation to prevent rapid spread, he added. \n", "\n", "This may be particularly feasible as geographical hotspots seem to be far apart based on official data. More than 80 per cent of the active cases are in five states - Maharashtra, Tamil Nadu, Delhi, Gujarat and Madhya Pradesh - and more than 60 per cent of the cases are in five cities, including Mumbai, Delhi and Ahmedabad. \n", "\n", "\"These hotspots should maintain at least a partial lockdown state and enforce strict social distancing to prevent massive spread and large-scale death particularly of the elderly and the sick,\" said Dr Ray. \n", "\n", "According to Dr Ray, it is essential to follow scientific guidelines but open up the economy to mitigate further financial disaster. \n", "\n", "India is a country with millions still below the poverty line and a few million who are the lower middle class who depend on day to day earnings to provide two square meals to their family and children, he noted. \n", "\n", "\"Our information about what COVID-19 has changed to a large extent on what we had known before. COVID-19 being a new disease, a lot was unknown about this disease,\" he said, adding that strategies to maintain physical distance, wash hands, and try to avoid touching your face, including wearing masks, especially in crowded places, can mitigate most of the spread.\n"]], "tags": ["Narendra Modi", "Columbia University", "The World Health Organisation", "University of Washington", "Union home ministry", "the union health ministry"]},
{"heading": [["Covid, non-Covid trash! Fast-filling yellow bins keep medi-waste handlers on their toes"]], "sub_heading": [["Corporate and government offices, which are resuming operations after the two-month lockdown, have been advised by various state-level Pollution Control Boards to take the help of bio-medical waste handlers to dispose-off \u201cdisinfectant consumables\u201d and anti-Covid safety gears used by their employees while on duty. This may add to the workload of medi-waste handlers."]], "time": [["Last Updated: Jun 01, 2020, 11.28 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["Bio-medical waste management companies, which usually collect hospital refuse but are increasingly disposing of waste related to the ", "Covid-19", " virus outbreak, may be in for a tough workload over the coming weeks.\n", "\n", "As corporate and government offices resume operations after a two-month lockdown, they have been advised by various State-level Pollution Control Boards to seek the services of bio-medical waste handlers to dispose of \u201cdisinfectant consumables\u201d and safety gear used by employees while treating Covid-19 infected patients.\n", "\n", "Bio-medical waste management firms are already working double shifts in cities such as Mumbai, Delhi and Chennai to clear out huge piles of routine and Covid-19 related waste discarded by hospitals, special Covid-19 care centres, containment spots and quarantine zones.\n", "\n", "Additional garbage from offices as well as private medical dispensaries, clinics and dentist chambers \u2013 which have begun opening up in non-containment zones \u2013 may add to the workload of bio-medical waste handlers.\n", "\n", "\u201cOur workload has increased over the past one month,\u201d said Amit Nilawar of SMS Envocare, which covers more than 125,000 hospital beds across Mumbai, Delhi, Raipur and Lucknow, of which over 50,000 hospital beds are in Mumbai alone.\n", "\n", "\u201cWe\u2019re facing a lot of practical problems\u2026 Several of our workers are not able to come for work due to the absence of public transport. Many are not coming back because their family members are not allowing them to return to work. In some cases, neighbours and landlords are asking our workers to stop doing this work,\u201d Nilawar said.\n", "\n", "\u201cWe\u2019re also not getting mechanics to repair or take up maintenance of our vehicles and other machines,\u201d he added.\n", "\n", "Bio-medical refuse disposal is a specialized branch within waste management.\n", "\n", "Waste generated by hospitals, nursing homes and local clinics are not handled by people clearing household garbage -- these institutions are required to hire bio-medical waste handlers to clear their bins.\n", "\n", "Now, even corporate and government offices have been advised to hire these firms to dispose of masks, gloves and other personal protective equipment used by staff. Worn-out \u201cdisinfectant consumables\u201d such as wipes, rags, disinfectant containers, mops are also required to be handed over to medical waste handlers.\n", "\n", "\u201cWe\u2019re gearing up to meet demand from corporates as well\u2026 Handling bio-medical refuse from offices is a new segment for us \u2013 and it is expected to grow significantly in the coming months,\u201d said Masood Mallick, joint MD at Ramky Enviro Engineers \u2013 one of India\u2019s largest waste management companies serving over 35,000 healthcare establishments.\n", "\n", "\u201cEvery consumable used for Covid-19 checks, as well as those worn for protection in offices and discarded, would go into a yellow bin. Medical waste handlers would collect the waste from offices and dispose them,\u201d said Mallick, whose company operates over 22 waste treatment facilities across the country.\n", "\n", "Yellow bins are an important part of Covid-19 waste management protocol as these contain \u2018infectious waste.\u2019\n", "\n", "Anatomical, chemical and soiled wastes, discarded linens, used laboratory wares and medical safety wear end up in yellow bins across hospitals, care centres \u2013 now, even offices. This is done to prevent the spread of infection and enable safe disposal and prevent reuse/repackaging of infected medical supplies.\n", "\n", "\u201cThere\u2019s a need to make companies aware of the need for waste segregation,\u201d said Nilawar of SMS Envocare. \u201cSince this is a new thing, companies tend to mix up general waste with used ", "PPE", " kits, masks and gloves. This should not happen,\u201d he added.\n", "\n", "\n", "\n", "ET spoke to nearly half-a-dozen bio-medical waste management firms, but none could provide an estimate of the quantity of Covid-19 waste collected across the country each day.\n", "\n", "State governments and local administrative bodies have directed these firms not to divulge Covid-19 related data publicly \u2013 including data pertaining to Covid-19 waste.\n", "\n", "However, it is evident that there is pressure on waste handlers operating in Covid-19 hot-spots across the country.\n", "\n", "\u201cWe do two collection rounds across key hospitals in the city\u2026 Sometimes, we get calls to clear bins at night; then it becomes three times a day,\u201d the manager of a bio-medical waste management firm operating in Chennai said.\n", "\n", "\u201cWe\u2019ll get swamped with work once private nursing homes open\u2026 We\u2019ll have to work round the clock to collect/dispose of the waste,\u201d he added.\n", "\n", "Bio-medical wastes are disinfected and autoclaved (sterilised) or incinerated at these facilities.\n", "\n", "The government has ordered Covid-19 wastes to be disinfected before incineration.\n", "\n", "In the normal course, syringes, blood and urine bags, intravenous sets and tubes, cotton swabs and bandages, and suture needles are autoclaved and mutilated.\n", "\n", "With Covid-19 trash, no one is taking chances.\n", "\n", "\u201cThe quantity of waste collected from hospitals, Covid-19 facilities and quarantine zones is significant\u2026 But we\u2019ll be able to manage the increasing loads,\u201d Mallick of Ramky Enviro Engineers said.\n", "\n"]], "tags": ["covid", "medical waste disposal", "waste disposal", "PPE", "coronavirus"]},
{"heading": [["PM Modi says advancements nations make in health sector will matter more than ever"]], "sub_heading": [["Addressing an event at the Rajiv Gandhi Health University in Bengaluru via video conference, he sought a discussion on whether new models can be conceived that make telemedicine popular on a larger scale."]], "time": [["Last Updated: Jun 01, 2020, 02.29 PM IST"]], "publisher": [["PTI"]], "article": [["The world must unite and focus on \"humanity-centric\" aspects of development, Prime Minister ", "Narendra Modi", " said on Monday, noting that advancements nations make in the health sector will matter more than ever as countries battle the COVID-19 pandemic.\n", "\n", "Modi also sought discussion on advances in ", "telemedicine", ", use of 'Make in India' products and IT tools in the medical sector for a healthier society.\n", "\n", "Addressing the 25th anniversary celebrations of the Rajiv Gandhi University of Health Sciences in Bengaluru via video, he said today the world is facing one of the biggest crisis since the two world wars.\n", "\n", "Like the world changed pre and post-World Wars, the same way the \"pre and post COVID\" world will be different, he said.\n", "\n", "In these times, Modi said the world is looking up to doctors, nurses, medical staff and scientific community with hope and gratitude.\n", "\n", "\"The world seeks both care and cure from you,\" he said.\n", "\n", "Seeking a global approach to deal with the health crisis, the prime minister said earlier, the debates on globalisation have focused on economic issues.\n", "\n", "\"Now, the world must unite and focus on humanity- centric aspects of development. Advancements nations make in the health sector will matter more than ever before,\" he told the gathering.\n", "\n", "He said there were three things on which he would urge \"maximum discussion and participation\" and these include telemedicines, Make in India products in the health sector and use of IT-based tools.\n", "\n", "He proposed work on new models that make telemedicine popular on a larger scale.\n", "\n", "\"The other is related to 'Make in India' in the health sector. The initial gains make me optimistic,\" he said.\n", "\n", "Domestic manufacturers have started production of ", "personal protective equipment", " and have supplied about one crore PPEs to COVID warriors, he pointed out. \n", "\n", "He said similarly, manufacturers have supplied 1.2 crore 'Make in India' N-95 masks to all the states.\n", "\n", "He also referred to the Aarogya Setu app to drive home his point on the use of IT tools for healthier societies.\n", "\n", "\"Twelve crore health conscious people have downloaded it. This has been very helpful in the fight against ", "coronavirus", ",\" Modi said.\n", "\n", "The prime minister also referred to cases of violence against healthcare personnel, saying such behaviour is not acceptable.\n", "\n", "\"Due to mob mentality, those working on the front-lines, those on duty be it doctors, nurses, Safai workers, others are subject to violence. I want to state it clearly - violence, abuse and rude behaviour is not acceptable,\" he asserted\n", "\n", "An ordinance was recently issued to punish those involved in such incidents.\n", "\n", "During the last six years, the government took various initiatives in health care and medical education, he said, adding that the work has been divided into \"four pillars\".\n", "\n", "He said preventive healthcare is the first pillar and it includes importance to Yoga, Ayurveda and general fitness.\n", "\n", "The second pillar relates to affordable healthcare and Ayushman Bharat- the world's largest healthcare scheme -- is a fine example of it.\n", "\n", "In less than two years, one crore people have benefitted from it.Women and those staying in villages are among the major beneficiaries of this scheme, he noted.\n", "\n", "\"The third pillar is improvements on the supply side. A nation like ours has to have proper medical infrastructure and medical education infrastructure.Work is underway to ensure a medical college or post-graduate medical institute in every district of the country,\" he said. The country, Modi said, has seen rapid progress in setting up of 22 more AIIMS.\n", "\n", "\"Over the last five years, we have been able to add over thirty thousand seats in MBBS and fifteen thousand seats in post-graduation. This has been the largest increase in the five year term of any government since Independence,\" he said.\n", "\n", "The fourth pillar, he said, is \"mission mode implementation,\" of programmes.\n", "\n", "The central government has recently approved the introduction of a new law for expanding education of more than 50 different allied and healthcare professionals.\n", "\n", "This law, once passed, will address the shortage of para-medical personnel in the country. It will also help India in supplying skilled resources to other countries, he said.\n", "\n", "\n"]], "tags": ["Arogya Setu", "Narendra Modi", "telemedicine", "personal protective equipment", "Rajiv Gandhi Health University", "coronavirus"]},
{"heading": [["Four or more dosage of HCQ showed significant decline of COVID-19 among healthcare workers: ICMR study"]], "sub_heading": [["As healthcare workers deputed in the treatment of coronavirus patients are at the higher risk of contracting virus, a pivotal study done by India's apex medical research body has revealed a significant reduction (>80 per cent) in the odds of COVID19 infection in the HCWs was identified with the intake of six or more doses of HCQ prophylaxis."]], "time": [["Last Updated: Jun 01, 2020, 08.38 AM IST"]], "publisher": [["ANI"]], "article": [["NEW DELHI: Citing noteworthy benefits of Hydroxychloroquine (HCQ) prophylaxis against coronavirus, ", "the Indian Council of Medical Research", " (ICMR) has revealed that the consumption of four or more doses of the antimalarial drug- (HCQ), has shown a significant decline of COVID19 infection among health care workers (HCWs).\n", "\n", " As ", "healthcare", " workers deputed in the treatment of coronavirus patients are at the higher risk of contracting virus, a pivotal study done by India's apex medical research body has revealed a significant reduction (>80 per cent) in the odds of COVID19 infection in the HCWs was identified with the intake of six or more doses of HCQ prophylaxis.\n", "\n", " Hence, to compare the risks and protective factors against coronavirus infection among HCWs in India, the researchers at ICMR have conducted a case-control investigation. The findings of the study are published in the latest issue of ", "the Indian Journal of Medical Research", ".\n", "\n", " In the study participants (healthcare workers) were identified in two groups- (i) diagnosed as positive (cases), (ii) negative (controls) for covid19. They were randomly selected from the countrywide COVID-19 testing data portal maintained by the ICMR. A 20-item brief-questionnaire elicited information on place of work, procedures conducted and use of ", "PPE", ".\n", "\n", " At least 624 and 549 healthcare workers were contacted for case and control groups respectively, out of which 60.58 per cent of cases (378/624) and 67.94 per cent of controls (373/549) were available for analysis as remaining participants did not pick up phone calls, wrong numbers, ineligible candidates (not HCWs), consent refusal to name a few.\n", "\n", " The document noted: \"The intake of four or more maintenance doses of HCQ, the protective effect started emerging, and in the adjusted multivariate model, a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the HCWs was identified with the intake of six or more doses of HCQ prophylaxis. This dose-response relationship added strength to the study outcomes,\" stated the findings adding that HCQ prophylaxis should be taken in tandem with PPE use as indicated by the multivariate model.\n", "\n", " However, the paper mentioned that simply initiating HCQ prophylaxis did not reduce the odds of acquiring COVID19 infection among HCWs.\n", "\n", " \"About 172 cases and 193 controls reported HCQ intake and no significant difference in the occurrence of adverse drug reactions\" was noted.\n", "\n", " The three most common side effects of HCQ as reported by the cases and controls were nausea, headache and diarrhoea. While none of the controls on HCQ complained of palpitations, only one case reported the same. Very few cases and controls had skin rashes after consuming HCQ,\" the paper said.\n", "\n", " According to ", "the National Task Force", " for COVID-19 in India recommended once a week maintenance dose for seven weeks (400 mg once weekly), following the loading dose (400 mg bd).\n", "\n", " The study stated that in the absence of clinical trial results on the safety and efficacy of HCQ chemoprophylaxis in the HCWs. The findings of the study offer evidence of public health importance.\n", "\n", " \"Higher prevalence of COVID19 infection in the HCWs has been a global concern, including in countries such as Spain, Italy and the USA, which further underscores the importance of the present findings,\" it read.\n", "\n", " In conclusion, public health message on the role of HCQ prophylaxis for the prevention of coronavirus infection among HCWs emerging from this study should be considered with the existing understanding of risk homoeostasis operating at individual levels, it said.\n", "\n"]], "tags": ["PPE", "the national task force", "The Indian Journal of Medical Research", "The Indian Council of Medical Research", "healthcare"]},
{"heading": [["India far away from peak, much better positioned in COVID-19 fight than other nations: Govt"]], "sub_heading": [["Lav Agarwal said it is wrong to just look at the total number of cases and state that India has the seventh highest number of cases as the population of countries also should be taken into account. "]], "time": [["Last Updated: Jun 02, 2020, 09.45 PM IST"]], "publisher": [["PTI"]], "article": [["India is far away from the peak of ", "COVID-19 spread", " and its preventive measures have been \"very effective\", putting it in a much better position in comparison with other countries, the government said on Tuesday, even as the case count and death toll continued to mount.\n", "\n", "Asked about India's status in the fight against ", "COVID-19", " and if certain areas have entered the community transmission phase, ", "Indian Council of Medical Research", " (", "ICMR", ") scientist ", "Nivedita Gupta", " at a media briefing said, \"Instead of using the word community transmission, it is important to understand the extent of spread of the disease and where do we stand in comparison with other countries.\"\n", "\n", "ICMR is conducting a sero-survey to assess the extent of spread of COVID-19 and almost 34,000 people are being tested as a part of it, she said, adding that its results will be out in the public domain by the end of this week or early next week.\n", "\n", "Asked when the peak in COVID-19 outbreak will arrive, Gupta said, \"We are very far away from the peak. Our preventive measures to curtail the disease are very effective and we are better positioned in comparison with other countries. You will get to see the data in a week.\"\n", "\n", "Joint Secretary in the Health Ministry Lav Agarwal, at the briefing, said it is wrong to just look at the total number of cases and state that India has the seventh highest number of cases as the population of countries also should be taken into account.\n", "\n", "About 14 most affected countries with a cumulative population almost equal to that of India have reported 55.2 times more COVID-19 deaths and 22.5 times more cases, he said.\n", "\n", "\"Our ", "COVID-19 fatality rate", " is 2.82 per cent as against 6.13 per cent globally. Our COVID-19 fatality rate is amongst the lowest in the world. We have been able to achieve this due to timely identification of cases and proper clinical management,\" Agarwal said.\n", "\n", "He also said that India's COVID-19 case fatality rate per lakh population is 0.41 per cent as against 4.9 per cent globally which is also amongst the lowest in the world.\n", "\n", "There are countries with a figure as high as 62 (Spain) and 82 (Belgium), he added.\n", "\n", "Presenting an age profile analysis of COVID-19 deaths, Agarwal said one in every two COVID-19 deaths in India has been of senior citizens who constitute 10 per cent of the total population.\n", "\n", "This ten per cent of India's population accounts for 50 per cent of India's COVID-19 linked deaths, while 73 per cent of COVID-19 deaths in the country are of people with comorbidities.\n", "\n", "\"Our analysis shows that people at high risk from COVID-19 are elderly people and those with comorbidities,\" he said, highlighting that it was imperative that high-risk people take required preventive measures and timely action based on medical advice in case they experience COVID-19 symptoms.\n", "\n", "He also urged the high risk population to stay at home and adopt various activities like yoga, reading books or developing indoor hobbies among others to utilise their time productively at home and stay fit.\n", "\n", "Precautions and laid down do's and dont's have to be followed with same vigour and momentum as India is opening up gradually, Agarwal said.\n", "\n", "\"As India fights coronavirus, it is necessary to keep up the momentum in the fight against COVID-19, let us take a pledge and declare it on social media as well. Use 'IndiaWillWin' hashtag to create awareness,\" he said.\n", "\n", "\"As we are in 'Unlock 1' situation, the challenge before us is how to follow COVID-appropriate behaviour, be it in terms of travel or office functioning. We have to think in terms of a new normal on how to live with the virus by taking adequate precautions so as to protect ourselves from it,\" he said.\n", "\n", "The ICMR scientist said 1.20 lakh samples are being tested for COVID-19 on an average per day and at present there are 476 government and 205 private labs testing for the virus.\n", "\n", "Responding to a question on whether there is some amount of under-reporting of COVID-19 deaths with several states not testing bodies for the infection, Gupta said there was no under-reporting of COVID-19 deaths in India and states were doing causality assessment and attributing cause of death accordingly.\n", "\n", "Agarwal also asserted that there is \"no under reporting of COVID-19\n", "\n", "When asked that the country is approaching 2 lakh cases and if there has been any change in the protocol for contact tracing, Agarwal said the primary focus remains on COVID-19 containment zones, identifying cases and active search for cases.\n", "\n", "\"With additional cases getting reported the size of zones may need to increase and active search may need to be strengthened depending on the number of cases,\" he said.\n", "\n", "\"After doing this active search, whichever cases including asymptomatic high risk contacts need to be tested as part of the testing criteria and anybody who is found positive should be treated as per protocol,\" Agarwal said.\n", "\n", "The novel coronavirus death toll rose to 5,598 in India on Tuesday with 204 more fatalities, while 8,171 new cases reported in the last 24 hours took the number of infections to over 1.98 lakh till Tuesday 8 AM, according to the Health Ministry.\n", "\n", "The recovery rate has improved from 11.42 per cent on April 15 to 26.59 per cent on May 3 and to 38.29 per cent on May 18, the ministry said.\n", "\n"]], "tags": ["nivedita gupta", "Indian Council of Medical Research", "Coronavirus cases in India", "plb ask tds tds", "ICMR"]},
{"heading": [[]], "sub_heading": [[]], "time": [[]], "publisher": [["ET Online"]], "article": [[]], "tags": []},
{"heading": [["US exit may hit WHO\u2019s India work"]], "sub_heading": [["\u200bThe US is the largest donor to the WHO with a contribution of $400 million in 2018-19. WHO India\u2019s country budget was reported to be a little above $100 million. An official aware of the development of WHO India office said there would be a short-term impact on the finances of the country office. "]], "time": [["Last Updated: Jun 02, 2020, 07.04 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["Mumbai: The US withdrawal from the ", "World Health Organization", " might hurt ", "WHO", " work in the field of ", "tuberculosis", " and other immunisation programs in India as financials show India along with a few African countries was the recipient of a bulk of American contribution.\n", "\n", " The US is the largest donor to the WHO with a contribution of $400 million in 2018-19. WHO India\u2019s country budget was reported to be a little above $100 million. An official aware of the development of ", "WHO India", " office said there would be a short-term impact on the finances of the country office. \n", "\n", "An email sent to WHO India office remained unanswered. Leena Menghaney, a lawyer with Doctors without Borders, told ET, \"I think we need WHO more than before as we get ready to negotiate access of critical drugs and vaccines for Covid-19 for low and middle income countries.\u201d \n", "\n"]], "tags": ["India WHO", "WHO India", "Tuberculosis", "World Health Organization", "who"]},
{"heading": [["India should now shift focus from number of cases to mortality curve: Experts"]], "sub_heading": [["The number of new Covid-19 cases is still rising though rate of recovery has improved to 47 per cent, from 42 per cent a week ago. Leading virologists and epidemiologists say lockdown fatigue is setting in, and that is why the new solution to deal with the crisis should be sustainable."]], "time": [["Last Updated: Jun 02, 2020, 07.08 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["Mumbai: Experts say the central and state governments should focus on protecting the elderly, identifying clusters of ", "Covid-19", " and devising local strategy as the remaining lockdown measures are eased to put the battered economy back on track.\n", "\n", "The number of new Covid-19 cases is still rising though rate of recovery has improved to 47 per cent, from 42 per cent a week ago. Leading virologists and epidemiologists say lockdown fatigue is setting in, and that is why the new solution to deal with the crisis should be sustainable.\n", "\n", "Leading virologist Jacob John, who works at ", "Christian Medical College", ", Vellore, told ET that it is time for the country to shift focus to the mortality curve from the epidemic curve (number of cases). Srinath Reddy, president of the Public Health Foundation of India, agreed.\n", "\n", "\u201cAs long as deaths are contained, we are getting the milder experience of the epidemic,\u201d Reddy said.\n", "\n", "Data available on Monday morning showed India\u2019s total number of active Covid-19 cases, or those still under treatment, was 93,322, while total recoveries stood at 91,819 and deaths from the disease, 5,394.\n", "\n", "\n", "India\u2019s Covid-19 mortality rate has come down in the last few weeks to 2.83 per cent from 3 per cent, which is similar to the global average.\n", "\n", "Reddy, who is also part of the National Covid-19 Task Force of the Indian Council of Medical Research (ICMR), said state governments need to focus on testing figures, which tell the number of tests done and how many new cases were found due to it; syndromic surveillance, where community health workers are put to work to track new cases; and look at hospitalisation of people coming in with severe respiratory problems. According to Reddy, India should no longer take doubling rate as criteria to look at the progression of the disease, because as the number goes up, the doubling rate is bound to get longer.\n", "\n", "John of CMC said that like with HIV, the government should raise awareness not only of the general public but also healthcare workers. \n", "\n", "Giridhar Babu, an epidemiologist who is part of the research group of ICMR on surveillance, told ET that evidence over the last two months suggests that clusters are responsible for the super spreading events.\n", "\n"]], "tags": ["Epidemiology", "giridhar babu", "Christian Medical College", "Virology"]},
{"heading": [["'Have adequate facilities, but we are ramping up hospital capacity by 40%'"]], "sub_heading": [["CK Mishra, chairman of the empowered group on hospital availability, disease surveillance, testing and critical care, said India\u2019s Covid-19 count will plateau with people\u2019s effort to cut down transmission."]], "time": [["Last Updated: Jun 02, 2020, 08.46 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["CK Mishra, chairman of the empowered group on hospital availability, ", "disease surveillance", ", testing and critical care, said India\u2019s Covid-19 count will plateau with people\u2019s effort to cut down transmission. Mishra, who is also the outgoing Union environment secretary, discusses the government\u2019s Covid-19 strategy in this interview with \n", ". Excerpts:\n", "\n", "\n", " \n", "In hindsight, there will be many views and it will be a matter of public health debate. At the time the lockdown came, there was a challenge and it was felt that the lockdown was best to address it. And there are huge dividends from that--from initially cutting transmission to reducing deaths and giving time for preparation.\n", "\n", "At the end of the day, the government has to slowly allow people to resume their life. A huge responsibility is now on the people. \n", "\n", "\n", "\n", " It is not as if the infections will end by the month-end. Fresh infections as well as positive rate will increase, especially as we ramp up testing - this is nothing to be alarmed about. The progression of the disease is fortunately not exponential and we are on predictable lines to far.\n", "\n", " Several modeling forecasts point at a July-August peak.\n", "\n", "Also, beyond a timeframe, the number of Covid infections becomes irrelevant.. The numbers will plateau by people\u2019s effort to cut down transmission.\n", "\n", "What becomes relevant for the government is management of cases, control of death rates.\n", "\n", "We have a mortality rate of 3-4% as on date; not more than 6-7% of the affected are in hospitals\u2014as per our learning over the last two and half months. In the Indian context, our recovery rate is very good.\n", "\n", "Given this trend, our concentration is, and should be, on treatment in hospitals and creating enough capacities to check mortalities.\n", "\n", " \n", "\n", " Our ability to withstand the virus is much better than other countries. There could be several reasons from ", "BCG", ", etc., to it, but it is a fact, so far.\n", "\n", "There was excessive focus on ventilators, keeping the western experience in mind, but we shifted the narrative to availability of ", "oxygen", " beds, which has served us well with higher recovery rates.\n", "\n", "This also clearly shows that country-specific strategy is key.\n", "\n", "\n", "\n", "When we started, our strategies were uniform and all-India in nature. Now we have started shifting strategies to cities. One of the reasons for the problems in ", "Delhi", " and Mumbai is density. So they need different treatment from a district, and that is being done for a fortnight now. Containment zones have been identified and enforcement has to be steered there to ensure there is no spread out.\n", "\n", "\n", "\n", "Yes, Uttar Pradesh, Bihar, West Bengal and Odisha saw a sudden spurt in cases. However, we have also seen that even if they did have infection, hardly any of these people needed serious hospitalisation and they recovered on their own. So, the virus did travel with the movement of people but hasn\u2019t caused the kind of damage it was expected to cause. Once the disease cycle is over, they will not shed and spread it to rural areas. Covid-19 is still - up to 85% - an urban phenomenon.\n", "\n", " \n", "\n", "There are mainly two reasons for states testing less--some states, particularly in the eastern part of country, did not have adequate testing infrastructure and, hence, couldn\u2019t ramp up testing. Here we pushed in alternative technology like ", "TRUNAT", " machines, and this has been addressed.\n", "\n", "However, there were also states like Telangana and Gujarat where the testing was low despite presence of infrastructure. They have begun picking pace on testing again, but more needs to be done.\n", "\n", "Tamil Nadu\u2019s numbers are very high but their management of cases is quite good and, hence, their death rate is among the lowest. At one point, Gujarat deaths went up--and the issue was hospital-level case management. So containment and hospital case management are key.\n", "\n", "\n", "Leaving aside a few cities, the majority of hospitals in the country have adequate facilities. Our district-wise analysis shows ", "adequate facilities", " and we are creating an alternative arrangement to ensure additional 40% capacity. However, we will keep over preparing to meet any scenario.\n", "\n", "\n", "\n", "A key learning is that the state of urban health infrastructure is a cause of worry. In Mumbai, that is borne out clearly--both in terms of density and health capacities and investment in them. The Smart City mission must redesign itself to meet health infrastructure demands and municipalities need to be focussed on, especially in urban areas.\n", "\n", "Also, we have not prepared ourselves for any outbreak of this nature. No coherent strategy was in place, because after the plague, we were dealing with sporadic outbursts, say of dengue, chikungunya and nipah, which were geographically specific. Preparation and capacity creation should have been all India level.\n", "\n", "The biggest takeaway is that this is a opportunity to redefine and strengthen the health system. It is also critical to decide on how the partnership between public and private sector will move ahead in the country.\n", "\n", "\n", "The private sector associated themselves with this issue and come together with government but I don\u2019t think we have been able to exploit their full potential of the private sector for various reasons from logistics to availability of doctors. They flagged off concerns on testing to us and we could address most of these - you now have 200 private labs testing for the virus. There are issues around financial liquidity which we are trying very hard to address. We may probably need a joint platform to address issues of concern.\n", "\n", "\n", "I am extremely concerned and pained on this issue as the overwhelming COVID-19 focus has left many people who need regular health monitoring without this care. More than 60% people go to clinics for their regular checks and it is essential that they open up immediately and even offer telemedicine. This needs a joint effort with the private sector.\n", "\n"]], "tags": ["TruNat", "BCG", "adequate facilities", "Delhi", "Oxygen", "Disease Surveillance"]},
{"heading": [["Made-in-India health gear makes me feel optimistic: PM"]], "sub_heading": [["\u201cThe initial gains make me optimistic,\u201d Modi said referring to Make-in-India initiatives in the healthcare sector in his address to the Rajiv Gandhi University of Health Sciences (RGUHS), virtually inaugurating its silver-jubilee celebrations from Delhi."]], "time": [["Last Updated: Jun 02, 2020, 11.04 AM IST"]], "publisher": [["ET Bureau"]], "article": [["Narendra Modi", "domestic manufacturers", "Make-in-India", "coronavirus", "ASYMPTOMATIC CASES", "telemedicine", "\n", "\n"]], "tags": ["telemedicine", "Narendra Modi", "coronavirus", "domestic manufacturers", "asymptomatic cases"]},
{"heading": [["Bihar to give 2.5 million HCQ tablets"]], "sub_heading": [["The ICMR has been pushing for the use of HCQ to prevent the spread of Covid-19 infection among frontline workers and, last month, it expanded the scope of the antimalarial medicine\u2019s use. "]], "time": [["Last Updated: Jun 02, 2020, 08.21 AM IST"]], "publisher": [[", ET Bureau"]], "article": [["NEW DELHI:The ", "Nitish Kumar government", " in Bihar has ordered distribution of more than 2.5 million ", "hydroxychloroquine", " (", "HCQ", ") tablets among nearly 240,000 frontline workers in the state while Uttar Pradesh has decided to run mobile medical units in villages to test ", "migrant workers", " for Covid-19.\n", "\n", "Both these states have seen a sharp increase in cases following the return of migrants. The Indian Council of Medical Research (ICMR) has been pushing for the use of HCQ to prevent the spread of Covid-19 infection among frontline workers and, last month, it expanded the scope of the antimalarial medicine\u2019s use. \n", "\n", "In this backdrop, the Bihar government issued an order on May 29 saying an additional 108,000 paramilitary and police personnel posted in various districts of the state will be given more than 600,000 HCQ tablets. This will be in addition to 1.8 million HCQ tablets being distributed in Bihar to nearly 130,000 paramedical staff and accredited social health activists (ASHAs), as per the letter accessed by ET. The highest distribution of HCQ will be in ", "East Champaran", ", Gaya, Samastipur, ", "Muzaffarpur", ", ", "Patna", ", Madhubani, Vaishali, Darbhanga and West Champaran districts.\n", "\n", "UP is also stepping up testing in the wake of nearly 2.5 million migrants returning to the state, by deciding to run mobile medical units in vehicles in villages where migrants have returned in large numbers, in cities where a high number of cases have been reported and in containment zones. These mobile medical units will offer testing for Covid-19 and will be stationed in the identified areas daily from 8 am to 5 pm, as per the order issued by the state government on May 29. \n", "\n", "These mobile medical units will also offer medicines to people suffering from influenza-like symptoms and check oxygen levels of such patients with oxymeters, the government has ordered. The medical personnel posted in such mobile medical units will be given proper personal protection equipment or PPE to carry out the tasks.\n", "\n"]], "tags": ["East Champaran", "Nitish Kumar government", "Hydroxychloroquine", "HCQ", "migrant workers", "Nitish Kumar", "Muzaffarpur", "patna"]},
{"heading": [[]], "sub_heading": [[]], "time": [[]], "publisher": [["ET Online"]], "article": [[]], "tags": []},
{"heading": [["Max completes healthcare merger with Radiant Life"]], "sub_heading": [["\u201cMax India shall stand dissolved effective today,\u201d Max Healthcare said in a statement on Monday, adding that amalgamation and demergers as per the sanctioned scheme have been successfully completed."]], "time": [["Last Updated: Jun 02, 2020, 01.11 PM IST"]], "publisher": [["ET Bureau"]], "article": [["New Delhi: Max India on Monday said it has completed spinning off its hospital assets under Max Healthcare and all its residual businesses under ", "Advaita Allied Health Services", ", along with merger of healthcare business of ", "Radiant Life", " Care with Max Healthcare.\n", "\n", "The process is in line with a composite merger scheme approved by ", "the National Company Law Tribunal", " (", "NCLT", "), the company said in a BSE filing.\n", "\n", "\u201cMax India shall stand dissolved effective today,\u201d Max Healthcare said in a statement on Monday, adding that amalgamation and demergers as per the sanctioned scheme have been successfully completed.\n", "\n", "The combination of Radiant and Max Healthcare, called ", "Max Health Institute", " (", "MHIL", "), will be the second-largest hospital network in the country by revenue and one of the top three chains in terms of bed capacity, the company said.\n"]], "tags": ["Max healthcare and radiant life merger", "max health institute", "the national company law tribunal", "Radiant Life", "advaita allied health services", "MHIL", "nclt"]},
{"heading": [["Physical distancing, masks, eye protection may help prevent COVID-19: Lancet study"]], "sub_heading": [["The systematic review of existing evidence was commissioned by the World Health Organization, the researchers said."]], "time": [["Last Updated: Jun 02, 2020, 11.36 AM IST"]], "publisher": [["PTI"]], "article": [["Toronto: ", "Physical distancing", " of two metres or more can prevent person-to-person transmission of ", "COVID-19", ", according to a comprehensive review of studies published in The ", "Lancet", " journal, which also found that face ", "masks", " and eye protection may decrease the risk of infection too. The systematic review of existing evidence was commissioned by the ", "World Health Organization", ", the researchers said. \n", "\n", " \"Physical distancing likely results in a large reduction of COVID-19,\" said lead author Holger Schunemann, professor at the McMaster University in Canada. \n", "\n", " \"Although the direct evidence is limited, the use of masks in the community provides protection, and possibly ", "N95", " or similar respirators worn by health care workers suggest greater protection than other face masks,\" said Schunemann, who is also co-director of the WHO Collaborating Centre for Infectious Diseases, Research Methods and Recommendations. \n", "\n", " The researchers noted that the availability and feasibility and other contextual factors will probably influence recommendations that organisations develop about their use, and eye protection may provide additional benefits. \n", "\n", " The international collaborative of researchers sought direct evidence on COVID-19 and indirect evidence on related coronaviruses causative of Severe Acute Respiratory Syndrome (SARS) and ", "Middle East Respiratory Syndrome", " (MERS). \n", "\n", " They identified no randomised control trials addressing the three coronaviruses but 44 relevant comparative studies in health-care and non-health-care settings across 16 countries and six continents from inception to early May 2020. \n", "\n", " The researchers noted more global, collaborative, well-conducted studies of different personal protective strategies are needed. \n", "\n", " For masks, large randomised trials are underway and are urgently needed, they said. \n", "\n", " \"There is an urgent need for all caregivers in health-care settings and non-health-care settings to have equitable access to these simple personal protective measures, which means scaling up production and consideration about repurposing manufacturing,\" said Derek Chu, a clinician scientist at McMaster University and an affiliate of the Research Institute of St. Joe's Hamilton. \n", "\n", " \"However, although distancing, face masks, and eye protection were each highly protective, none made individuals totally impervious from infection and so, basic measures such as hand hygiene are also essential to curtail the current COVID-19 pandemic and future waves,\" Chu added.\n"]], "tags": ["physical distancing", "masks", "N95", "Middle East Respiratory Syndrome", "lancet", "World Health Organization"]},
{"heading": [[]], "sub_heading": [[]], "time": [[]], "publisher": [[]], "article": [[]], "tags": ["Hydroxychloroquine", "CSIR", "HCQ", "shekhar mande", "who"]},
{"heading": [[]], "sub_heading": [[]], "time": [[]], "publisher": [["Reuters"]], "article": [[]], "tags": []}
]